CURRICULUM VITAE April 2013

DANIEL IAN KAUFER

EDUCATION/TRAINING: • Certification in Behavioral Neurology & Neuropsychiatry, United Council of Neurological

Specialties, October 23, 2006. • Board Certified, American Board of Psychiatry and Neurology (Neurology), May 30, 1995; re-

certified September 2005 • Neurobehavior / Geriatric Neurology Fellowship, University of California-Los Angeles

Department of Neurology, Neurobehavior Program, Los Angeles, CA; West Los Angeles Veterans Affairs Medical Center, Department of Psychiatry, Section of Behavioral Neuroscience, July 1992-June 1995.

• Resident in Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, July 1989-July 1992.

• Transitional/Medicine Internship, Montefiore Hospital, Pittsburgh, PA, June 1988-June 1989. • University of Wisconsin Medical School, Madison, WI: M.D. degree, May 1988. • University of Wisconsin-Madison, Madison, WI: B.S. Cum Laude (Molecular Biology and

Zoology), May 1983.

PROFESSIONAL EXPERIENCE – EMPLOYMENT HISTORY: 2003- Founding Director, UNC Memory Disorders Program, Department of Neurology,

University of North Carolina at Chapel Hill School of Medicine. 2003- Associate Professor (Tenured 2007), Department of Neurology, University of North

Carolina School at Chapel Hill School of Medicine. 1999-2003 Assistant Professor, Neurology and Psychiatry, University of Pittsburgh School of Medicine. 1999-2003 Associate Director, Clinical Core, Alzheimer Disease Research Center, University of Pittsburgh Medical Center. 1999-2003 Consulting Physician, Neurology, Mayview State Psychiatric Hospital, Bridgeville, PA. 1997-1998 Associate Director, Geriatric Behavioral Neurology/Neuropsychiatry Fellowship, Western Psychiatric Institute and Clinics, University of Pittsburgh Medical Center. 1996-2003 Member, Center for the Neural Basis of Cognition, University of Pittsburgh-Carnegie-

Mellon University Consortium. 1995-2003 Director, Dementia Treatment Clinic Alzheimer Disease Research Center, University of

Pittsburgh Medical Center. 1995-1999 Assistant Director, Clinical Core, Alzheimer Disease Research Center, University of Pittsburgh Medical Center. 1995-1999 Assistant Professor of Psychiatry and Neurology, University of Pittsburgh School of Medicine. 1992-1995 Clinical Instructor, Department of Neurology, University of California-Los Angeles School of Medicine.

HONORS / AWARDS:

2

• President, Society for Behavioral and Cognitive Neurology, 2007-2009. • Fellow, American Academy of Neurology, 2007. • Fellow, American Neuropsychiatric Association, 2005. • Best Doctors in America, 2005-present. • Presidential Award, Neurological and Behavioral Sciences, for paper “Assessing the effects of

donepezil in Alzheimer’s patients and its impact on caregivers”. American Geriatrics Society, May 1998.

• Merck-AGS New Investigator Award, for paper “Circadian Sleep Disturbances in Normal Elderly, Alzheimer’s patients, and Their Caregivers”, American Geriatrics Society, May 1998.

• Augustus Rose Fellowship, The John Douglas French Alzheimer’s Foundation, for project “Clinical Predictors of Response to Tacrine in Alzheimer’s Disease”, (October 1996 to September 1998).

• Merck-AFAR Geriatric Pharmacology Fellowship for project “Biological Response Markers of Response to Tacrine in Alzheimer’s Disease: Acute and Chronic Studies”, (July 1996 to June 1998).

• American Neuropsychiatric Association Young Investigator Award, October 1995. • University of Wisconsin-Madison Committee on Undergraduate Education Award For Academic

Excellence, in recognition of Senior Honors Thesis “Pharmacological and Biochemical Properties of Cholinergic Receptors in the Nematode Ascaris lumbricoides, April 1982.

• Knapp Honors Undergraduate Research Fellowship, summer 1981. • National Merit Semi-Finalist.

BIBLIOGRAPHY:

BOOK CHAPTERS: 1. Khandewahl C, Kaufer DI, Sloane PD. “Alzheimer’s and Other Dementias.” In: Ham’s Primary

Care Geriatrics, 6th edition. P Sloane, ed. New York: Elsevier, in press. 2. Kaufer DI. “Agnosia.” In: Encyclopedia of the Neurosciences, M Aminoff, R Daroff, eds. New

York: Academic Press, in press. 3. DeBrigard F, Giovanello KS, Kaufer DI. “Neuroanatomy of Memory.” In: Behavioral Neurology &

Neuropsychiatry, D. Arciniegas, C. Filley. C. Anderson, eds. New York: Cambridge University Press, 2013:161-173.

4. Sloane PD, Kaufer DI, Khandelwal C. “Cognitive Impairment.” In: Essentials of Family Medicine, PD Sloane, LM Slatt, MH Ebell, MA Smith, D Power, AJ Viera, eds. Baltimore: Lippincott Williams & Wilkins, 2012:269-82.

5. Possin KL, Kaufer DI. Parkinsonian Dementias. AAN Continuum, 2010. 6. Kaufer DI, DeKosky ST. “Diagnostic classifications: relationship to the neurobiology of dementias.”

In: Neurobiology of Mental Illness, 3nd ed. DS Charney & E Nestor eds. New York: Oxford University Press, 2009:895-907.

7. DeKosky ST, Kaufer DI, Wolk D, Hamilton R, Lopez OL. “The Dementias.” In: Neurology in Clinical Practice, 5th Edition, W Bradley, R Daroff, G Fenichel, J Jankovic, eds. Philadelphia: Butterworth-Heinemann, 2008:1855-1908.

8. Kaufer DI. “Frontal lobe anatomy: dorslolateral and cingulate cortex.” In: The Human Frontal Lobes: Function and Disorders, 2nd ed., BL Miller, JL Cummings, eds., New York: Guilford, 2007:44-58.

9. Arciniegas DA, McAllister TW, Kaufer DI. “Cognitive Impairment.” In: Guide to Neuropsychiatric Therapeutics, CE Coffey, T McAllister, J Silver, eds., Philadelphia: Lippincott, Williams & Wilkins, 2007:224-78.

3

10. Tröster AI, Kaufer DI. “Dementia in Parkinson’s disease.” In: Psychiatric Issues in Parkinson’s Disease. M Menza, L Marsh, eds, Taylor & Frances, 2005:77-96.

11. DeKosky ST, Kaufer DI, Lopez OL. “The Dementias.” In: Neurology in Clinical Practice, 4th Edition, W Bradley, R Daroff, G Fenichel, J Jankovic, eds. Philadelphia: Butterworth-Heinemann, 2004:1901-1952.

12. Kaufer DI. DeKosky ST. “Diagnostic classifications: relationship to the neurobiology of dementias.” In: Neurobiology of Mental Illness, 2nd ed. DS Charney, E Nestor, BS Bunney, eds. New York: Oxford University Press, 2004:771-782.

13. Kaufer DI, Cummings JL. “Delirium and dementia: an overview.” In: Behavioral Neurology and Neuropsychology, 2nd ed. T Feinberg, M Farah, eds., New York: McGraw-Hill, 2003:495-514.

14. Kaufer DI. “Agnosia.” In Encyclopedia of the Neurosciences, M Aminoff, R Daroff, eds. New York: Academic Press, 2003; vol. 1:57-9.

15. Kaufer DI. “Alzheimer’s disease: focus on the cholinergic system.” In: The Neurochemistry of Consciousness, E Perry, H Ashton, A. Young, eds., Amsterdam: John Benjamin, 2002:229-246.

16. Kaufer DI. “Clinical diagnosis of dementia with Lewy bodies.” In: Mapping the Progress of Alzheimer’s and Parkinson’s Disease. Y. Mizuno, I. Hanin, A. Fischer, eds., New York: Kluwer Academic / Plenum, 2002:473-476.

17. Kaufer DI, Cummings JL. “Dementia: an overview.” In: Patient-Oriented Approaches in Cognitive Neuroscience, T Feinberg, M Farah, eds:, Cambridge (MA): MIT Press, 2000:355-368.

18. Kaufer DI. DeKosky ST. “Diagnostic classifications: relationship to the neurobiology of dementias.” In: Neurobiology of Mental Illness: Dementia, DS Charney, E Nestor, BS Bunney, eds. New York: Oxford University Press, 1999:641-649.

19. Kaufer DI, Lewis DA. “Frontal lobe anatomy and cortical connectivity.” In: The Human Frontal Lobes: Function and Disorders, BL Miller, JL Cummings, eds., New York: Guilford Press, 1999:27-44.

20. Kaufer DI, Cummings JL. “Delirium and dementia: an overview.” In: Behavioral Neurology and Neuropsychology, T Feinberg, M Farah, eds., New York: McGraw-Hill, 1996:499-520.

21. Kaufer DI, Cummings JL. “Personality alterations in degenerative brain disorders.” In: Neuropsychiatry of Personality Disorders, J Ratey, ed. Cambridge, MA: Blackwell Scientific Publications;1995:172-209.

PEER-REVIEWED ARTICLES: 1. Cheng B, Zhang D, Chen S, Kaufer D, Shen D. "Semi-supervised multimodal relevance vector

regression improves cognitive performance estimation from imaging and biological biomarkers", Neuroinformatics 2013 Mar 16 (online).

2. Boxer A, Knopman, D, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Shapira J, Kerwin D, Lerner A, Wu W-C, Koestler M, Sullivan K, Nicholson R. Ullah J, Neuhaus J, Mesulam MM, Miller B. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149-56.

3. Giovanello KS, De Brigard FD, Ford JH, Kaufer DI, Burke JR, Browndyke JN, Welsh-Bohmer KA. Event-related functional magnetic resonance imaging changes during relational retrieval in normal aging and amnestic mild cognitive impairment. J Int Neuropsychol Soc. 2012;24:1-12.

4. Kaufer, DI. How does looking the other way portray executive dysfunction in frontotemporal degeneration? Neurology 2012;78:1806-8.

5. Kotagal V, Muller MLTM, Kaufer DI, Koeppe RA, Bohnen NI. Subcortical cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders, Neurosci Letters 2012; 514(2) :169-72.

6. Piven J, Rabins P; Autism-in-Older Adults Working Group. Autism spectrum disorders in older adults: toward defining a research agenda. J Am Geriatr Soc. 2011;59:2151-5.

4

7. Kurtz AI, Kaufer DI. Dementia in Parkinson’s disease. Curr Treat Options Neurol. 2011;13:242-54. 8. Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, Lenze EJ,Holm M,

Rogers JC, Mazumdar S, Houck PR, Begley A, Anderson S, Karp JF, MillerMD, Whyte EM, Stack J, Gildengers A, Szanto K, Bensasi S, Kaufer DI, Kamboh MI, Dekosky ST. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry. 2011;68:51-60.

9. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: the caregiver experience of clinical care. Parkinsonism Relat Disord. 2010;16:388-9.

10. Lin P-J, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer’s case definitions using Medicare claims and survey data. Alzheimers Dement., 2010; 6:334-41.

11. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit, SH. Lewy body dementia: caregiver burden and unmet needs. Alzheimer Dis Assoc Disord. 2010;24:177-81.

12. Kaufer D, Gandy S. APOE(epsilon4) and Bapineuzumab: infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 2009;73:2052-2053.

13. Lin P-J, Biddle AK, Ganguly R, Kaufer DI, Maciejewski ML. The concentration and persistence of health care expenditures and prescription drug expenditures in Medicare beneficiaries with Alzheimer’s disease and related dementias. Medical Care 2009;47:1174–1179.

14. Kaufer DI, Williams SC, Braaten AJ, Gill K, Zimmerman S, Sloane PD. Cognitive screening for dementia and mild cognitive impairment in assisted living: comparison of three tests. J Am Med Dir Assoc, 2008;9:586-93.

15. Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer’s disease treatments: a descriptive review. Alzheimers Dement. 2008;4:49-60.

16. Kaufer DI, Tröster AI. Chapter 29 Neuropsychology of dementia with Lewy bodies. Handb Clin Neurol. 2008;88:549-66.

17. Royall DR, Lauterbach EC, Kaufer D, Malloy P, Coburn KL, Black KJ. The cognitive correlates of functional status: a review from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatr Clin Neurosci. 2007;19:249–265.

18. Zimmerman, S, Sloane PD, Williams CS, Dobbs D, Ellajosyula, R, Braaten AJ, Rupnow MFT, Lehman ME, Kaufer DI. Residential care/assisted living staff may detect undiagnosed dementia using the Minimum Data Set Cognition Scale (MDS-COGS), J Am Geriatr Soc. 2007;55:1349-55.

19. Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007;78:641-3.

20. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer’s disease: a systematic review and meta-analysis. Drugs and Aging, 2007; 24:155-67.

21. Arciniegas DB, Kaufer DI, and the Joint Advisory Committee on Subspecialty Certification of the American Neuropsychiatric Association and the Society for Behavioral and Cognitive Neurology. Core curriculum for subspecialty certification in Behavioral Neurology & Neuropsychiatry. J Neuropsychiatr Clin Neurosci, 2006;18:6-13.

22. Huang X, Chen PC, Kaufer DI, Troster A, Poole C. Apolipoprotein E role in dementia in Parkinson’s disease: a meta-analysis. Neurology, 2006;63:189-193.

23. Hoekert M, Riemersma-van der Lek RF, Swaab DF, Kaufer DI, Van Someren EJW. Comparison between informant observed and actigraphic assessment of sleep-wake rhythm disturbances in demented elderly residents of homes for the elderly. Am J Geriatr Psychiatr, 2006;14:104-111.

24. Marshall GA, Shchelchkov E, Kaufer DI, Ivanco L & Bohnen NI. White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. Acta Neurol Scand, 2006;1387-91.

25. Marshall GA, Hendrickson R, Kaufer DI, Ivanco LS, Bohnen NI. Cognitive correlates of brain MRI subcortical signal hyperintensities in non-demented elderly. Int J Geriatr Psychiatry. 2006; 21:32-5.

26. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis CA, Davis

5

JG, Moore RY, DeKosky ST. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol, 2006;253:242-47.

27. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka KI, Lee V M-Y, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ,Yamada M, for the Consortium on DLB. Dementia with Lewy Bodies: Diagnosis and Management: Third Report of the DLB Consortium, Neurology, 2005;65:1863-1872.

28. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005;59:473-7.

29. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Davis JG, Constantine G, Mathis CA, Moore RY, DeKosky ST. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer¹s disease. Neurosci Lett. 2005;380:127-132.

30. Kaufer DI, Borson S, Kershaw P, Sadik K. Reduction of caregiver burden in Alzheimer disease by treatment with galantamine, CNS Spectrums, 2005;10:481-488.

31. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ. Koeppe RA, Meltzer CC, Constantine G, Davis JG, Mathis CA, DeKosky ST, Moore RY. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005;76:315-319.

32. Kaufer DI. A case study in the treatment of dementia with Lewy bodies. Acta Psychiatr Scand 2004; 110:73-76 (includes invited comment).

33. Marshall GA, Kaufer DI, Lopez OL, Rao GR, Hamilton RL, DeKosky ST. Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 2004;75:1396-1400.

34. Bohnen N, Kaufer D, Hendrickson R, Ivanco L, Moore R, DeKosky S. Effects of donepezil on motor function in patients with Alzheimer disease. J Clin Psychopharmacol. 2004;24:354-6.

35. Perez-Madrinan G, Cook SE, Saxton JA, Miyahara S, Lopez OL, Kaufer DI, Aizenstein HJ, DeKosky ST, Sweet RA. Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. Am J Geriatr Psych 2004;12:449-456.

36. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST. Cortical cholinergic function is more severely affected in parkinsonian dementia than Alzheimer’s disease: an in vivo positron emission tomography study. Arch Neurol 2003;60:1745-1748.

37. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2003;15:346-353.

38. Cook, SE, Miyahara S, Bacanu SA, Perez-Madrinan G, Lopez OL, Kaufer DI, Nimgaonkar VL, Wisniewski SR, DeKosky ST. Psychotic symptoms in Alzheimer disease: evidence for subtypes. Am J Geriatr Psychiatr 2003;11:406-413.

39. Mendez OE, Shang J, Jungreis CA, Kaufer DI. Diffusion-weighted MRI imaging in Creutzfeldt-Jakob disease: a better diagnostic marker than protein 14-3-3? J Neuroimaging 2003;13:147-151.

40. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, DeKosky ST. Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer’s disease from 1983 to 2000. J Neuropsychiatry Clin Neurosci. 2003;15:67-73.

41. DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL, Becker JT, Daxton J, Klunk WE, Sweet R, Kaufer DI, Kamboh MI. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer’s disease: correlation with cognitive impairment. Ann Neurol 2003;53:81-90.

42. Sweet RA, Panchalingam K, Pettegre JW, McClure RJ, Hamilton RL, Lopez OL, Kaufer, DI, DeKosky ST, Klunk WE. Psychosis in Alzheimer disease; postmortem magnetic resonance

6

spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiology of Aging 2002;23:547-553.

43. Boada M, Cejudo JC, Tarraga L, Lopez OL, Kaufer D. Neuropsychiatric inventory questionnaire (NPI-Q): Spanish validation of an abridged form of the Neuropsychiatric Inventory (NPI). Neurologia 2002;17:317-23.

44. Kaufer DI. Cholinesterase-inhibitor therapy in dementia: novel clinical substrates and mechanisms of treatment response. CNS Spectrums 2002;7:742-750.

45. Sweet RA, Kamboh MI, Wisneski SR, Lopez OL, Klunk WE, Kaufer DI, Dekosky ST. Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis In Alzheimer’s disease. J Geriatr Psychiatr Neurol, 2002; 15:24-30.

46. Lopez OL, Becker JT, Kaufer DI, Klunk W, Sweet RA, Hamilton R, DeKosky ST. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002;59:43-47.

47. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase-inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002,72:310-314.

48. Hagerty JA, Kaufer DI. Cognitive and motor symptoms in dementia: focus on dementia with Lewy bodies, J Amer Acad Nurse Pract, 2002;14:398-404.

49. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, LaFrance WC Jr, Coffey CE. Executive control functions: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2002;14:377-405.

50. Sweet RA, Lopez OL, Hamilton RL, Wiesniewski SR, Healy M, Klunk WE, Kaufer DI, DeKosky ST. Psychotic symptoms in Alzheimer’s disease are not associated with more severe pathological features. International Psychogeriatrics, 2000, 12:547-558.

51. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton R, Kaufer DI, Sweet, Meltzer CC, Wisniewski S, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades. Neurology 2000;55:1863-1868.

52. Kaufer DI. Pharmacological therapy of dementia with Lewy bodies. J Geriatr Psychiatr Neurol 2002;15:224-232.

53. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton R, Kaufer DI, Sweet, Meltzer CC, Wisniewski S, Kamboh MI, DeKosky ST. Research evaluation of the diagnosis of possible Alzheimer’s disease over the last two decades. Neurology 2000;55:1854-1862.

54. LaFrance Jr. WC, Lauterbach EC, Coffey CE, Salloway SP, Kaufer DI, Reeve A, Royall DR, Aylward EA, Rummans TA, Lovell MR. The use of herbal alternative medicines in neuropsychiatry: a report of the ANPA Committee on Research. J Neuropsychiatr Clin Neurosci 2000;12:177-192.

55. Lopez OL, Wisniewski S, Hamilton RL, Becker JT, Kaufer DI, DeKosky ST. Predictors of progression in patients with AD and Lewy bodies. Neurology.2000; 54:1774-1779.

56. Lopez OL, Hamilton RL, Becker JT, Wisniewski S, Kaufer DI, DeKosky ST. Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies. Neurology 2000; 54:1780-1787.

57. Kaufer DI, Cummings JL, Smith V, Ketchel P, MacMillan A, Lopez OL, DeKosky ST. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12:233-239.

58. Kaufer DI. The effect of cholinergic therapy on neuropsychiatric symptoms in neurological disorders. Current Psychiatry Reports, 1999;1:78-84.

59. Rummans TA, Lauterbach EC, Coffey E, Royall D, Cummings J, Salloway S, Duffy J, Kaufer D. Pharmacologic efficacy in neuropsychiatry. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 1999;11:176-189.

60. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, Becker JT, DeKosky ST. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999;53:1292-1299.

61. Kaufer DI, Catt K, Lopez O, DeKosky ST. Dementia with Lewy bodies: response of delirium-like

7

features to donepezil. Neurology, 1998;51:1512. 62. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, MacMillan A, Ketchel P, Masterman D,

DeKosky ST. Assessing the impact of behavioral disturbances in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210-215.

63. Lauterbach EC, Cummings JL, Duffy J, Coffey CE, Kaufer D, Lovell M, Malloy P, Reeve A, Royall DR, Rummans TA, Salloway SP. Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. J Neuropsychiat Clin Neurosci 1998; 10:249-266.

64. Kaufer DI, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiaty Clin Neurosci 1998;10:55-63.

65. Lopez O, Kamboh I, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer’s disease. Neurology 1997;49:794-97.

66. Kaufer DI, Miller BL, Itti L, Fairbanks L, Li J, Fishman J, Kushi J, Cummings JL. Midline cerebral morphometry distinguishes frontotemporal dementia and Alzheimer’s disease. Neurology 1997;48:978-984.

67. Mega MS, Masterman DL, Benson DF, Vinters HV, Tomiyasu U, Craig AC, Foti DJ, Kaufer D, Scharre DW, Fairbanks L, Cummings JL. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996;47:1403-1409.

68. Cummings JL, Kaufer DI. Neuropsychiatric aspects of Alzheimer’s disease: The cholinergic hypothesis revisited. Neurology 1996;47:876-883.

69. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.

70. Kaufer DI, Mendez M, Mischel P, Verity AM, Benson DF. Alien hand syndrome in adult-onset orthochromatic leukodystrophy: disconnection of a limb from supplementary areas. Behavioural Neurology 1996;9:5-10.

71. Lopez OL, Kaufer D, Reiter CT, Carra, J, DeKosky ST, Palmer AM. Relationship between CSF neurotransmitter metabolites and aggressive behavior in Alzheimer’s disease. European Journal of Neurology 1996;3:153-155.

72. Aarsland D, Cummings JL, Kaufer D. Tacrine in Alzheimer’s disease: which patients and which mental functions improve? Alzheimer’s Research 1995;1:133-136.

SUBMITTED MANUSCRIPTS 1. Stepp A, Morris L, Rapp, CG, McCullough B, Kaufer DI. Assessing neuropsychiatric symptoms

with the NPI-Q: promise and pitfalls in aiding differential diagnosis and identifying caregiver concerns (under review).

2. Lathren C, Sloane PD, Hoyle J, Zimmerman S, Kaufer DI. Improving dementia diagnosis and practice patterns, and community linkages. (under review). PUBLISHED ABSTRACTS: 1. Boxer A, Knopman, D, Kaufer D, Grossman M, Onyike C, Graf-Radford N, Mendez M, Shapira J,

Kerwin D, Lerner A, Wu W-C, Koestler M, Sullivan K, Nicholson R. Ullah J, Neuhaus J, Mesulam MM, Miller B. A 26-week randomized multicenter placebo-controlled trial of memantine for behavioral variant frontotemporal dementia and semantic variant primary progressive aphasia. Alz Assoc., July 2012.

2. Beltran-Papsdorf T, Chapman B, Kaufer DI. Extending the spectrum of paraneoplastic antibodies

8

associated with AMPA receptor antibodies. Annual Meeting of the American Academy of Neurology, Honolulu, HI, April 13, 2011.

3. Beyea A, Coward HJ, Kaufer DI. The great pretender: epilepsy in the elderly. Poster presentation at the Annual Meeting of the American Geriatrics Society, May 13, 2011.

4. Khan F, Kaufer DI. The role of diffusion-weighted MRI imaging and other tests in diagnosing Creutzfeldt-Jacob disease. Poster presentation at the North Carolina Neurological Societ, Greensboro, NC, February 19, 2011.

5. Fan Y, Kaufer D, Shen D. Joint estimation of multiple clinical variables of neurologiccal diseases from imaging patterns. ISBI‘ 10 Proceedings of the 2010 IEEE International Conference on Biomedical Imaging. 2010.

6. Zamora E, Coward HJ, Kaufer DI. A 63 year old male with a “normal” MRI brain scan and progressive behavioral changes. Poster presentation at the Annual Meeting of the American Geriatrics Society, May 2010.

7. Kaufer DI, Liu F, Becker JT, Snitz E, Saxton J, DeKosky ST. Lopez OL. Accuracy-certainty memory profiles enhance discrimination among Alzheimer’s disease, mild cognitive impairment, and normal elderly controls. Neurology 2010;74 (Suppl 2):A505.

8. Stark A, Joran E, Kaufer DI. Diagnostic serendipity in evaluating normal-pressure hydrocephalus, Neurology 2010;74 (Suppl 2):A339.

9. Cordle A, Ostrander M, Kaufer, DI. MRI features mimicking limbic encephalitis and CJD in Hashimoto’s encephalopathy without paraneoplastic antibodies. Neurology 2010;74 (Suppl 2):A327.

10. Khandewal C, Kaufer DI, Wiggins B, Mitchell M, Sloane PD. A dementia educational intervention for primary care physicians: increasing cognitive and metacognitive competence. 62nd annual meeting of the Gerontological Society of America, Atlanta, GA, November 2009.

11. Leggett An, Zarit SH, Duda JE, Galvin JE, Kaufer DI, LIppa CF, Taylor A. Role strain, personal strain, and worry about performance among caregivers of people with Lewy body dementia. 62nd annual meeting of the Gerontological Society of America, Atlanta, GA, November 2009.

12. Giovanello KL, De Brigard F, Kaufer D., Browndyke J, Welsh-Bohmer K. Retrieval of item and relational memories in healthy aging and mild cognitive impairment. Annual meeting of the Society for Neuroscience, Chicago, IL, November 2009.

13. Fan Y, Kaufer D, Shen D, and the ADNI. Estimating clinical variables from brain images using Bayesian regression. International Conference on Alzheimer’s Disease. Vienna, Austria, Alzheimer’s & Dementia, July 2009.

14. Troster A, Fields J, McTaggart A, Williams R, Kaufer D. Quantitative and qualitative differences in visual confrontation naming in Parkinson’s disease with and without dementia and Alzheimer’s disease. Neurology, April 2009.

15. Galvin J, Duda J, Kaufer D, Lippa C, Taylor A, Zarit S. Lewy body dementia: the caregiver experience of care. Neurology, April 2009.

16. Kaufer DI, Yuen H, DeKosky ST, Klunk WE. Cerebellar amyloid in a case of early-onset dementia with a presenilin-1 mutation: correlation to clinical phenotype. Alzheimer Association 11th International Conference on Alzheimer’s Disease, Alzheimer’s & Dementia 2008;4(suppl 2):290-1.

17. Ivanco L, Kaufer DI, Hendrickson R, Bohnen NI. Modification of the Stroop Color Word Test better defines the executive cognitive deficit in non-demented patients with Parkinson’s disease. Neurology 2006;66(suppl 1).

18. Bohnen NI, Kaufer DI, Ivanco LS, Hendrickson R, Ivanco DE, Lopresti BJ, Mathis CA, DeKosky ST, Moore RY. Cholinergic denervation is associated with more severe depression in Parkinson’s disease. Neurology 2005; 64(suppl 1):A222.

19. Kaufer DI, Bohnen NI, Ivanco L, Hendrickson R, Lopresti B, Mathis CA, Moore RY, DeKosky ST. Cholinergic correlates of cognitive and neuropsychiatric disturbances in Parkinson’s disease with and without dementia. Neurology 2005;64 (suppl 1):A137-8.

20. Huang X, Chen PC, Kaufer DI, Troster A, Poole C. Apo E’s role in dementia in Parkinson’s disease: a meta-analysis. Neurology 2004; 62(suppl 5):A206-7.

9

21. Bohnen NI, Kaufer DI, Ivanco LS, Hendrickson R, Lopresti B, Mathis CA, Moore RY, DeKosky ST. Evidence for clinical threshold effect of donepezil-induced inhibition of cerebral acetylcholinesterase activity in Alzheimer’s disease: an in vivo PET study. Neurology 2004;62(suppl 5):A297-8.

22. Marshall GA, Shchelchkow E, Hendrickson R, Kaufer DI, Ivanco LS, DeKosky ST, Bohnen NI. Cognitive correlates of brain MRI subcortical signal hyperintensities in non-demented elderly. Neurology 2004;62 (suppl 5):A323.

23. Marshall GA, Shchelchkow E, Kaufer DI, Ivanco LS, DeKosky ST, Moore RY, Bohnen NI. Cerebral white matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. Neurology 2004; 62(suppl 5):A523-4.

24. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Mathis CA, Moore RY, DeKosky ST. Behavioral correlates of variability in cortical cholinergic activity in cognitively normal elderly. Neurology 2004; 62(suppl 5):A296.

25. Sioufi F, Ivanco LS, Kaufer DI, Hendrickson R, Lopresti B, Mathis CA, Moore RY, Bohnen NI. Striatal dopamine receptor expression in non-demented patients with Parkinson’s disease with and without neuropsychiatric comorbidity. Neurology 2004; 62(suppl 5):A304.

26. Moore RY, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Mathis CA, DeKosky ST, Bohnen NI. Cognitive correlates of cholinergic denervation in Parkinson’s disease without dementia. Neurology 2004; 62(suppl 5):A:321.

27. Kaufer DI, Marshall GA, Hanin I, Lopez OL, DeKosky ST. Cholinergic correlates of altered awareness in Alzheimer’s disease: a clinicopathological study. Neurology 2004; 62(suppl 5):A189.

28. Bohnen NI, Kaufer DI, Lopresti B, Mathis CA, Moore RY, DeKosky ST. Brain-region selective inhibition of acetylcholinesterase activity by donepezil in AD. Neurology 2003;60(Suppl 1):A412-413.

29. Bohnen NI, Kaufer DI, Ivanco LS, Hendrickson R, Lopresti B, Mathis CA, DeKosky ST, Moore RY. Syndromal differences in neurobehavioral correlates of cholinergic denervation in Alzheimer’s and Parkinson’s disease. Neurology 2003;60(Suppl 1):A143.

30. Kaufer DI, Sarles, CE., Saxton JA, Becker JT, DeKosky ST. Certainty-indexed memory assessment in MCI, normal elderly and Alzheimer’s disease. Neurology 2003;60(Suppl 1):A202.

31. Marshall GA, Kaufer DI, Lopez OL, Rao GR, Hamilton RL, DeKosky ST. A neuropathological correlate of anosognosia in Alzheimer’s Disease. Neurology 2003;60(Suppl 1):A196-197.

32. Kaufer DI, Bohnen NI, Lopresti B, Mathis CA, Moore RY, DeKosky ST. PET acetylcholinesterase imaging correlates with clinical response to donepezil treatment in parkinsonian dementia. Neurology 2003;60(Suppl 1):A414.

33. Bohnen N, Kaufer, D, Lopresti, B, Koeppe, R, Mathis, C, Moore RY, DeKosky ST. Cerebral acetylcholinesterase activity in patients with Parkinson’s disease with and without dementia and Alzheimer’s disease. J Nucl Med 2002;43:63P.

34. Bohnen N, Kaufer D, Lopresti B, Koeppe R, Meltzer C, Mathis C, Moore RY, DeKosky ST. Clinical, regional cerebral acetylcholinesterase and glucose metabolic changes after donepezil therapy in patients with Alzheimer’s disease. J Nucl Med 2002;43:63P.

35. Bohnen NI, Kaufer DI, Lopresti B, Mathis C, Moore RY. In vivo subcortical glucose metabolism and acetylcholinesterase activity in Parkinson’s disease with dementia. Neurology 2002;58(suppl 3):A354.

36. Wilson RK, Kaufer DI, Becker JT. Longitudinal analysis of a patient with non-fluent aphasia: A voxel-based morphometric study. Neurology 2002;58(suppl 3):A270.

37. Kaufer DI, Lingler JL, Ketchel PJ, Lopez OL, Dekosky ST. Cognitive and neuropsychiatric symptoms in Alzheimer’s disease: Differential relationship to global functioning and caregiver distress. Neurology 2002;58(suppl 3):A485-486.

38. Kaufer DI, Lingler JL, Ketchel PJ, Dekosky ST. Caregiver distress and neuropsychiatric symptoms in Alzheimer’s disease: Focus on fear and anxiety. J Am Geriatr Soc, 2002;50 (suppl 1):s167-168.

39. Chow Tsz Ming, Kaufer DI, Lopez OL, Hamilton RL, Becker JT,, DeKosky ST. Temporal

10

evolution of the “Lewy Body” phenotype in autopsy-confirmed cases of Alzheimer’s disease and dementia with Lewy bodies. Neurology 2001;56(suppl 3):A300-301.

40. Kaufer DI, Ketchel P, Lopez OL, Reynolds CF, DeKosky ST. Circadian sleep and neuropsychiatric disturbances in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci, 2001; 13:1137.

41. Chow Tsz Ming, Kaufer DI. Effect of donepezil on aphasia, agnosia, and apraxia in patients with cerebrovascular disease. J Neuropsychiatry Clin Neurosci, 2001; 13:140.

42. Kaufer DI, Hamilton RL, Lopez OL, DeKosky ST. White matter hyperintensities and cerebral amyloid angiopathy in a case of Dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci, 2000.

43. Kaufer DI. Core neuropsychiatric response profile to cholinergic therapy in Alzheimer’s disease: clinical and neurobehavioral relevance. Neurology, 1999;52 (suppl 2):A182.

44. Kaufer DI, Cummings JL, Smith V, Ketchel P, MacMillan A, Lopez OL, DeKosky ST. Assessing neuropsychiatric manifestations in clinical practice: the Neuropsychiatric Inventory Questionnaire (NPI-Q), Journal of Neuropsychiatry and Clinical Neuroscience 1999;11:145-146.

45. Catt K, Kaufer DI. Dementia with Lewy bodies: Response of psychosis and hypersomnolence to donepezil. J Am Geriatr Soc 1998;46:S81.

46. Kaufer DI, Catt K, Pollock BG, DeKosky ST. Assessing the effects of donepezil in Alzheimer’s patients and its impact on caregivers. J Am Geriatr Soc 1998;46:S66.

47. Kaufer DI, Reynolds CF, Hall F, Ketchel P, Buysee D. Circadian sleep disturbances in normal elderly, Alzheimer’s patients, and their caregivers. J Am Geriatr Soc 1998; 46:S11.

48. Kaufer DI, Catt K, Pollock BG, Lopez OL, DeKosky ST. Donepezil in Alzheimer’s disease: Relative cognitive and neuropsychiatric resposnses and their relationship to caregiver distress. Neurology,1998, 50:A89.

49. Kaufer DI, Miller BL, Li J, Cummings JL. Differential regional SPECT perfusion deficits in frontotemporal dementia and Alzheimer’s disease. J Neuropsychiatr Clin Neurosci 1997;9:699.

50. Kaufer DI, Catt K, Lopez OL, Pollock BG, DeKosky ST. Response to donepezil in Alzheimer’s disease: noncognitive symptoms and caregiver distress. J Neuropsychiatr Clin Neurosci 1997; 9:698.

51. Kaufer DI, Cummings JL. Neuropsychological concomitants of extrapyramidal signs and psychosis in Alzheimer’s disease. J Int Neuropsychol Soc 1997;3:22.

52. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S. Assessing the caregiver impact of neuropsychiatric symptoms in Alzheimer’s disease: The Neuropsychiatric Inventory Caregiver Distress Scale. J Neuropsychiatr Clin Neurosci 1997;9:173

53. Kaufer DI, Itti L, Miller BL, Fairbanks L, Li J, Fishman J, Cummings JL. Midline cerebral morphometry discriminates frontotemporal dementia and Alzheimer’s disease. Neurology 1996:46:A186.

54. Kaufer DI, Mendez M, Vinters H, Mischel P, Benson DF. Apraxia in a left-hander with rapidly progressive asymmetric white matter disease. J Neuropsychiatr Clin Neurosci 1995;7:404.

55. Kaufer DI, Cummings JL. Response of behavioral symptoms in Alzheimer’s disease to tacrine. J Neuropsychiatr Clin Neurosci 1995;7:397.

56. Kaufer DI, Hinkin C, Kalechstein A, Smushkovich E, Cummings J. Frontal-subcortical syndrome with Arnold-Chiari malformation: Response to fluoxetine. J Neuropsychiatr Clin Neurosci 1995;7:404.

57. Kaufer DI, Cummings JL. Does dementia severity predict response to tacrine in Alzheimer’s disease? Neurology 1995;45 (suppl 4):A471-A472.

58. Kaufer DI, Benson DF. Neuropsychiatric manifestations of global auditory agnosia. Neurology 1994;44(suppl 2):A400.

59. Kaufer DI, Lopez OL, Palmer AM, DeKosky ST. CSF correlates of neurobehavioral symptoms in Alzheimer’s disease. Neurology 1993;43 (suppl 2):A173.

INVITED ARTICLES:

11

1. Taylor A, Kaufer DI. The Role of Palliative and Hospice Care in Lewy Body Dementia. LBDA.org, February 2011.

2. Kaufer DI. Alzheimer’s Demands Greater Diagnostic Precision. The Triangle Physician, Nov. 2010:12-13.

3. Galvin JE, Boeve BF, Duda JE, Galasko D, Kaufer DI, Leverenz JB, Lippa CF, MD6, Lopez OL, representing the Scientific Advisory Council of the Lewy Body Dementia Association. Current Issues in Lewy Body Dementia Diagnosis, Treatment, and Research. LBDA.org, May 2008.

4. Kaufer DI. Cutting edge of Alzheimer’s disease therapy. US Neurological Disease 2006. BTH Touch Press, 2006:2-4.

5. Braaten AJ, Kaufer DI. Dementia with Lewy bodies: a case study in diagnosis and treatment. Neurology & Cognitive Neuroscience, 2005;5-7.

6. Grossberg GT, Borson S, Kaufer DI, Farlow MR. Cholinesterase inhibitors across stages of dementia and cognitive impairment in the elderly. CNS Spectrums 2005;10(suppl 6):1-10.

7. Arciniegas DB, Lauterbach E, Anderson K, Chow TW, Flashman L, Hurly R, Kaufer DI, McAllister TW, Reeve A, Schiffer RB, Silver JM.The differential diagnosis of pseudobulbar affect (PBA): distinguishing PBA among disorders of mood and affect. CNS Spectrums 2005;10(suppl4):1-14.

8. Kaufer DI, Longo FM. Treating Alzheimer’s: Have the rules changed? Practical Neurology 2004;3:24-32.

9. Kaufer DI. Pharmacologic treatment expectations in the management of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;17(suppl 1):32-39.

10. Kaufer DI. Alzheimer’s disease. ElderCare 2002, 2:1-4. 11. Kaufer DI. Long-term care in dementia: patients and caregivers. Clinical Cornerstone 2001;3:52-62. 12. Kaufer DI. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase-

inhibitors on neuropsychiatric symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9(suppl 2):8-14.

13. Kaufer DI. Dementia with Lewy Bodies: diagnosis and treatment. Revista Neurologia 1998 27 (suppl 1):S67-71.

14. Kaufer DI. Treatment of noncognitive symptoms in Alzheimer’s disease. Revista Neurologia 1998 27 (suppl 1):S48-51.

15. Cummings JL, Kaufer DI. Brief screening tools for dementia assessment. The Center for Advanced Medical Education, 1998.

16. Kaufer DI. “Dementia with Lewy Bodies”, Mediguide to Geriatric Neurology, Lawrence DellaCorte Publications, 1997, Vol. 1, issue 5.

OTHER PUBLICATIONS: Book Forward:

“Treasures In the Darkness: Maintaining Early-Stage Alzheimer’s, Parkinson’s, and Lewy Body Dementia,” Pat Snyder, author, Amazon Press, 2012.

Refereed Presentations (unpublished):

1. Kaufer DI, Pollock BG, Lopez OL, DeKosky ST. Caregiver assessment of treatment response to donepezil. Free Communication platform presentation at the World Psychiatric Association meeting, Hamburg, Germany, August 7, 1999.

2. Kaufer DI, Cummings JL. Neuropsychological concomitants of extrapyramidal signs and psychosis in Alzheimer’s disease. Platform presentation, Annual Meeting of the International Neuropsychological Society, Orlando, FL, February 5, 1997.

3. Foti D, Kaufer D, Martinez C, Mendez M, Noffsinger D. Linguistic and non-linguistic processing in Alzheimer’s disease: relationship to attentional and central auditory function. Poster presented at

12

Cognitive Neuroscience Society meeting, San Francisco, CA, April 1996. 4. Kaufer D, Martinez C, Foti D, Mendez M, Noffsinger D. Auditory processing asymmetry in

Alzheimer’s disease. Poster presented at Cognitive Neuroscience Society meeting, San Francisco, CA, April 1996.

5. Kaufer D, Nuwer M, Benson DF. Two cases of generalized auditory agnosia: electrophysiological distinction and neurobehavioral correlates, platform presentation, American Electroencephalographic Society Annual Meeting, Chicago, IL, September, 20, 1994.

6. Kaufer D, Lopez O, Palmer A, DeKosky S. CSF markers of psychotic symptoms in dementia. Poster presented at American Psychiatric Association meeting, San Francisco, CA, May 27, 1993.

Book Reviews: 1. “Geriatric Neurology” (pre-press review), Oxford University Press, 2012. 2. “Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, Ed. D.

Dickson, in Cognitive & Behavioral Neurology, 2007; 20:78. 3. “Dementia. Presentations, Differential Diagnosis, and Nosology. 2nd ed. Authors V. Olga B. Emery,

PhD and Thomas E. Oxman, MD, in New England Journal of Medicine, 2004; 350:846. 4. “The Developing Mind: Towards a Neurobiology of Interpersonal Experience”, author Daniel J.

Siegel, in Archives of Neurology, 2000; 57:1081-1082. 5. “Functional Neuroanatomy and Clinical Neuroscience”, Cambridge University Press, 1999 (pre-

publication review). Project Report: Hansen RA, Gartlehner G, Kaufer DI, Lohr KN, Randolph LC, Carey T. Drug Class Review on Alzheimer’s Drugs: Final Report. RTI-UNC Evidence-Based Practice Center, sponsored by the Oregon Health & Science University, April 2005 (internet 2010).

Internet CME Publication: “Parkinson’s Disease with Dementia”, Interactive Clinical Update (case studies), Medscape Neurology and Neurosurgery, April 2005. International Plenary and Symposium Invited Presentations:

1. “Prolonged Release Formulation: Extending the Benefits of Galantamine.” Ninth International

Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, April 20, 2006.

2. “Case Presentations in Dementia and Lewy Bodies”, Third International Workshop on Dementia with Lewy Bodies and Parkinson’s Disease Dementia, Newcastle-upon-Tyne, UK, September 18, 2003.

3. “Dementia and Lewy Bodies”, Dementia Today: 3rd Barcelona-Pittsburgh Seminars, Barcelona, Spain, October 25, 2002.

4. “Diagnostic Criteria for Dementia with Lewy Bodies”, Fifth International Congress on Progress in Alzheimer’s and Parkinson’s Disease, Kyoto, Japan, April 4, 2001.

5. “Treatment of Behavioral Symptoms in Alzheimer’s Disease”, Dementia Today: Barcelona-Pittsburgh Seminars, Barcelona, Spain, October 6, 2000.

6. “Sleep Disturbances in Dementia”, Dementia Today: Barcelona-Pittsburgh Seminars, Barcelona, Spain, October 5, 2000.

7. “Sleep and Circadian Disruption in Alzheimer’s Disease and Dementia with Lewy Bodies”, 16th Annual Meeting of the British Sleep Society, Oxford, UK, September 16, 1999.

13

8. “Cholinergic Therapy for Alzheimer’s Disease”, Congreso Argentino de Neuropsiquiatria: Jornadas de la Enfermedad de Alzheimer, Buenos Aires, Argentina, September 6, 1999.

9. “Dementia with Lewy Bodies”, Congreso Argentino de Neuropsiquiatria: Jornadas de la Enfermedad de Alzheimer, Buenos Aires, Argentina, September 6, 1999.

10. “Acetylcholine and Behavioral and Psychological Symptoms in Dementia”, Plenary Session, Ninth Congress of the International Psychogeriatric Association, Vancouver, Canada, August 16, 1999.

11. “Beyond Cognition: Noncognitive Effects of Cholinergic Therapy in Alzheimer’s Disease”, Invited Symposium: Dementia, Pan American Congress 1999: Aging in the Americas, San Antonio, TX, February 22, 1999.

12. “The Neuropsychiatric Inventory: Comprehensive Assessment of Psychopathology in Dementia”, Aging 2000: Joint Meeting, International Psychogeriatric Association, Munich, Germany, September 14, 1998.

13. “Diagnosis and Treatment of Lewy Body Dementia: A New Challenge”, Dementia Today: Barcelona-Pittsburgh Seminars, Barcelona, Spain, May 29, 1998.

14. “Treatment of Noncognitive Symptoms in Alzheimer’s Disease”, Dementia Today: Barcelona-Pittsburgh Seminars, Barcelona, Spain, May 29, 1998.

15. “Metrifonate: Effect on Mood and Behaviour”. Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, April 19, 1998.

Other:

1. Kaufer DI, Barrett AM, Finney G, Hart J, D’Esposito M. Behavioral Neurology Strategic Plan, Behavioral Neurology section, American Academy of Neurology, September 2007.

2. Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology 2010;75:425-31. (Acknowledgement for assisting with survey content development and dissemination to the Behavioral Neurology section).

TEACHING RECORD MEDICAL STUDENT:

University of North Carolina at Chapel Hill:

A. Lectures:

1. “Neurodegenerative Cognitive Disorders”, MS II Brain & Behavior course, 2011-present. 2. “Neurocognitive Examination and Dementia Case Review“ lecture, monthly, Neurology MSIII

Clerkship, July 2007-present. 3. “Dementia / Cognitive Neurology Resident Conference”, monthly September 2010-present. 4. “Alzheimer’s Disease”. Clinical Capstone,” Neuroscience course, MS I (entire class), January,

2007-2010. 5. “Evaluating Language and Cognitive Disorders” lecture, 8 blocks/year, 20 students/block,

Psychiatry-Neurology MS III-IV Clerkship, July 2006-June 2007. 6. “Alzheimer’s Disease” lecture, Medical Neuroscience, MS II (entire class), 2006-2010. 7. “Altered States of Consciousness” lecture, Medical Neuroscience, MS II (entire class), 2004-2007. 8. “Movement Disorders” lecture, Medical Neuroscience, MS II (entire class), 2004.

B. Clinical Preceptor:

1. Neurology Ward Attending, 8-12 weeks /year, 2-4 students per rotation, 2003-present. 2. Memory Disorders Clinic, ad hoc basis, 2003-present.

14

C. Medical Student Research Elective:

1. Christine Schaeffer, MS I, U. of Cincinnatti Medical School, “Genetics of Alzheimer’s Disease”, Medical Student in Aging Research Training (MSTAR) T-35 grant, National Institutes of Aging, Summer 2013.

2. Anne Dunbar, MS IV, Neur 415: Cognitive Neurology & Dementia Elective, Sept 2012. 3. Amy Stepp, MS I, Medical Student Summer Research elective, “Developing an Integrated Database

for Clinical and Brain Imaging Data in Frontotemporal Degeneration,” Summer 2012. 4. Catherine Rogers, MS IV, Neur 415: Cognitive Neurology & Dementia Elective, October 2011. 5. Asa Cordle, MS IV, Neur 415: Cognitive Neurology & Dementia Elective, March 2011. 6. James Bateman, III Medical Student Summer Research elective “Qualitative Evaluation of a Novel

Memory Assessment to Predict Alzheimer’s Disease”, Summer 2009 (poster presentation, Medical Student Research Day, January 27, 2010).

D. Other:

1. Distinguished Medical Scholars Seminar Series: Pharmacologic Treatment for Cognitive Impairment - How Big is the Reward? Faculty Advisor, December 15, 2011.

University of Pittsburgh:

A. Lectures:

1. “Differential Diagnosis of Dementia” Case Conference Seminar Leader, Clinical Neuroscience Clerkship, MS III, 8 blocks/year, 20 students/block, July 1999 to April 2003.

2. “Mental Status Exam”, Lecture, Clinical Neuroscience Clerkship, MS III, 8 blocks/year, 20 students/block, July 1999 to April 2003.

3. “Alzheimer’s Dementia”, Medical Neuroscience course, MS II (160 students), 1998-2003. 4. “Language and the Brain”, Medical Neuroscience course, MS II (160 students), 1998-2003. 5. “Dementia and Delirium”, Medical Neuroscience course, MS II (160 students), 2001. 6. “Aphasia, Agnosia, and Apraxia”, Problem-Based Learning seminar (1.5 hour), MS II (160 students

1998-2003.

B. Clinical Preceptor:

• Neurology Ward Attending, 8 weeks /year, 2-4 students per rotation, 2000-2003. • Memory and Cognitive Disorders Clinic, ad hoc basis, 2003-present.

C. MS IV Elective Preceptor:

1. Robin Wilson, PhD, Behavioral Neurology Clinical / Research Elective, June 18 to August 4, 2001. 2. Ming-Tsz Chow: Integrated Life Science Clinical Neuroscience Clinical Research Preceptor, 2000

(1 month), Behavioral Neurology Clinical / Research Elective Rotation, 2000 (1 month). 3. Patty Wilkosz, PhD, Independent Study Elective Research, 2000 (1 month). 4. Sarah Berman, PhD, Behavioral Neurology Clinical Elective, 1999 (1 month). 5. Jordan Karp, Behavioral Neurology Clinical Elective, 1999 (1 month).

RESIDENT: University of North Carolina at Chapel Hill:

A. Lectures/Seminars:

1. “Cognitive Neurology & Dementia” (annual board review), 2006-present.

15

2. “Neurobiology of Dementia”, Neurobiology of Mental Illness Seminar, Department of Psychiatry, University of North Carolina at Chapel Hill, August 9, 2006.

3. “Memory and Higher Cognitive Functions”, Neuropsychiatry Seminar, Department of Psychiatry, University of North Carolina at Chapel Hill, November 16, 2005, January 17, 2007.

4. NeuroPsych Rounds, monthly case conference for Neurology and Psychiatry residents, University of North Carolina at Chapel Hill, September 2004 to June 2005.

5. “Differential Diagnosis of Dementia”, Neurology resident lecture (annual), University of North Carolina at Chapel Hill, 2003-present.

B. Clinical Preceptor

1. Neurology Ward Attending, 8 weeks /year, 3-5 residents per rotation, 2003-present. 2. Memory and Cognitive Disorders Clinic, 2003-present: 3. Specialty Clinic Rotations, 2010-present. 4. Jeffrey Frank, MD, 2012 (1 month) 5. Raza Khan, MD, 2006 (1 month). 6. Eric Lindzen, MD, 2005 (1 month). 7. Sunil Chauhan, MD, 2005 (1 month).

C. Faculty Advisor 1. David Delman, MD (2012-present) 2. Leonardo Morantes, MD (2011-present). 3. Aleksandra Stark, MD (2008-2011); currently Behavioral Neurology Fellow, Boston University. 4. Raza Khan, MD (2003-2006); currently Assistant Professor of Neurology, Howard University

Medical School. University of Pittsburgh:

A. Lectures/Seminars:

1. NeuroPsych Rounds, monthly case conference for Neurology and Psychiatry residents, September 2001 to June 2002.

2. “Behavioral Neuroanatomy” lecture, PGY-III Neuropsychiatry Seminar, Department of Psychiatry, 2001-2003.

3. Geriatric Psychiatry Case Conferences: 1997-2003: - WPIC In-Patient Geropsychiatry units, Robert Marin, MD, Supervisor, quarterly

- Benedum Geriatric Center (out-patient), Mark Miller, MD, Supervisor, quarterly. B. Clinical Preceptor: 1. Neurology Ward Attending, 8 weeks /year, 3-5 residents per rotation, 1999-2003. 2. Alzheimer Disease Research Center / Center for Excellence in Parkinson’s Disease: 3. Eric Farbman, MD. Clinical Elective, 2002 (1 month). 4. Gad Marshall, MD, Clinical Research Elective, 2002 (2 months). (currently Assistant Professor, 5. Neurology, Cognitive and Behavioral Neurology Division, Brigham & Womens’s Hospital). 6. Oscar Mendez, MD, Clinical Research Elective, 2002 (1 month). 7. Miguel Estevez, MD, PhD, Clinical Elective, 1999 (1 month).

FELLOW: University of North Carolina at Chapel Hill:

16

Clinical Preceptor:

1. Britni Hebert, MD, Geriatric Medicine Fellow, 2012-2013 (monthly) 2. Amy Denham, MD, Geriatric Medicine Fellow, 2012-2013 (monthly) 3. Catherine Hathaway, MD, Geriatric Medicine Fellow, 2011-12 (monthly) 4. Grant Williams, MD, Geriatric Medicine Fellow, 2011-12 (monthly) 5. Marvin McBride, MD, Geritric Medicine Fellow, 2011-12(monthly) 6. Annete Beyea, MD, Geriatric Medicine Fellow, 2010-2011 (monthly) 7. Lindsey Wilson, MD, Geriatric Medicine Fellow, 2010-2011 (monthly). 8. Matthew Kreps, MD, Geriatric Medicine Fellow, 2009-2010 (monthly). 9. Zeke Zamora, MD, Geriatric Medicine Fellow, 2009-2010 (monthly). 10. Laura Patel, MD, Geriatric Medicine Fellow, September 2008. 11. Michael LaMantia, MD, Geriatric Medicine Fellow, October 2008. 12. Leslie Schuenemann, MD, Geriatric Medicine Fellow, November 2008. 13. Christine Kandewal, MD, Geriatric Medicine Fellow, September 2008. 14. Sang Hyun Lee, MD, MPH, PhD, Geriatric Family Medicine Physician, Visiting Scholar, Clinical

Associate Professor, Yonsei University College of Medicine, Director of Health Promotion Center, Geriatric Clinic, Department of Family Medicine, NHIC ILSAN Hospital, South Korea, weekly, March to December 2005.

15. Beth Brubaker, MD, Geriatric Medicine Fellow, weekly, January to June 2005. 16. Nurum Erdum, MD, MPH, Geriatric Medicine Fellow, weekly, January to August 2004.

OTHER: University of North Carolina at Chapel Hill: 1. “Pathophysiology of Dementia: Clincial Update and Emerging Science”, Graduate Nursing Course

N715, UNC Chapel Hill, 2011-2. 2. “Dementia Overview”, Aging and Health 410, Multidisciplinary Program on Aging, UNC Chapel

Hill, 2011-12. 3. “Dementia Overview”, Neurodiagnostics and Sleep Science, Department of Allied Health

Sciences, UNC Chapel Hill, 2011-12. 4. Dissertation Committee: Pei-jung Lin, PhD candidate (conferred May 2008), “Predictive Modeling

of Healthcare Costs and Institutionalization for Medicare Beneficiaries with Alzheimer’s Disease”, Department of Health Policy Administration, School of Public Health, University of North Carolina at Chapel Hill, 2006-2008.

University of Pittsburgh: • Karyn Catt, MD , Geriatric Neuropsychiatry Fellowship Trainee, November 1996 to June 1998. • Jennifer Hagerty-Lingler, CRNP, John A. Hartford Building Academic Geriatric Nursing Capacity

Program Predoctoral Scholarship, 2001-2003 (Mentor).

POST-DOCTORAL NEUROPSYCHOLOGISTS: • Course instructor, Psychiatry Seminar 480: “Behavioral Neuroanatomy”, University of California at

Los Angeles School of Medicine, Department of Psychiatry & Biobehavioral Science, 1993-1994 (10 week seminar).

17

VISITING PROFESSOR: • University of Iowa, Department of Psychiatry, October 7-8, 2002:

o “Dementia and Lewy Bodies”. Department of Psychiatry Grand Rounds o “Awareness and Certainty: Cholinergic Connections?”, Research Seminar

• Visiting Professor Lecture, Department of Psychiatry, Susquehanna Medical System “New Perspectives on the Diagnosis and Treatment of Alzheimer’s Disease”, , Williamsport, PA, October 8, 1999.

• University of Newcastle, Department of Old Age Psychiatry, “Cholinergic Substrates of Behavioral Symptoms in Alzheimer’s Disease and Dementia with Lewy Bodies”, Newcastle-upon-Tyne, UK, September 13, 1999.

GRAND ROUNDS

University of North Carolina at Chapel Hill: 1. “Autoimmune Encephalopathies: Black, White, and Many Shades of Gray”. Neurology Grand Rounds, December 18, 2012. 2. “Normal-Presssure Hydrocephalus: Cases and Conundrums”, Neurology Grand Rounds, January 12, 2012. 3. “A Curious Case of Dubious Diagnoses and Therapeutic Tribulations”, Neurology Grand Rounds, September 22, 2011. 4. “Prion Disorders: How Do Misbehaving Proteins Propagate?” Neurology Grand Rounds, May 12, 2011. 5. “Aphasia Syndromes in Dementia”, Neurology Grand Rounds, November 4, 2010. 6. “From Eponymic Diseases to Spectral Proteinopathies: Dementia Comes of Age,” Psychiatry Grand Rounds, October 27, 2010. 7. “Diagnostic Serendipity in Evaluating Normal-Pressure Hydrocephalus“, Neurology Grand Rounds, October 22, 2009. 8. Lewy Body Dementia: Morbidity and Mortality”, Neurology Grand Rounds, December 11, 2008. 9. “Hunting Down Brain Amyloid: An Alzheimer’s Odyssey” Neurology Grand Rounds, September 4, 2008. 10. “Cognitive Screening in the Elderly: Can An Old Dog Learn New Tricks?” Neurology Grand Rounds, May 7, 2008. 11. “Circadian Sleep Disturbances in Alzheimer’s and Parkinson’s Disease”, Neurology Grand Rounds, September 13, 2006. 12. “Dementia Care: Why You Should”. Family Medicine Grand Rounds, March 20, 2006. 13. “Dementia Didactics: Pathos, Logos, Ethos”, Neurology Grand Rounds, December 7, 2005. 14. “Dementia with Lewy Bodies”, Neurology Grand Rounds, November 3, 2004. 15. “Posterior Cortical Atrophy”, Neurology Grand Rounds, September 8, 2004. 16. “Cholinergic Substrates of Dementia”, Psychiatry Grand Rounds, November 21, 2003. 17. “Affective Ataxia Without Anticipation in SCA-17”, Neurology Grand Rounds, July 8, 2003. Outside Hospitals: 1. “Non-AD Dementias”, Bryan ADRC Research Seminar, Duke University, Durham, NC, March 3,

2010. 2. “Parkinsonian Dementias: Focus on Lewy Body Disorders”, Department of Medicine Grand

Rounds, Carolinas Medical Center, Charlotte, NC, March 18, 2008. 3. “Dementia or Parkinsonism: Which Came First?” Neurology Grand Rounds, University of Alabama-

Birmingham, February 12, 2008.

18

4. “Neuroimaging of Alzheimer’s Disease: Diagnosing and Monitoring,” AHEC Teleconference, Rutherfordton, NC, October 12, 2007.

5. “Alzheimer’s Disease and Beyond: Where We’re Headed,” Department of Family Medicine Grand Rounds, Brody School of Medicine, Eastern Carolina University, Greenville, NC, May 17, 2007.

6. ”Cholinergic Correlates of Dementia: A Tale of Two Diseases.” Neurology Grand Rounds, Vanderbilt University, December 1, 2006.

7. “Managing Behavioral Symptoms in Dementia”, Grand Rounds, Black Mountain Center VA, Asheville, NC, April 7, 2006.

8. “Deconstructing Dementia and Lewy Bodies”, Neurology Grand Rounds, Emory University, January 9, 2006.

9. “Alzheimer’s Disease Diagnosis and Treatment”, Wilson AHEC, Roanoke Rapids, NC, November 4, 2005.

10. “Dementia and Lewy Bodies”, Neurology Grand Rounds, University of Michigan, Ann Arbor, MI, September 16, 2005.

11. “Dementia with Lewy Bodies”, Memory and Aging Program, Department of Neurology, University of California-San Francisco School of Medicine, February 6, 2004.

12. “Dementia Update”, Northeast Neurology Medical Center, Concord, NC, September 16, 2003. 13. “Cholinergic Therapy in Dementia: Novel Clinical Substrates”, Department of Rehabilitation

Medicine, Mercy Hospital, Pittsburgh, PA, September 18, 2002. 14. “Primary Progressive Aphasia”, Combined Neuroscience Conference, Departments of Neurology

and Neurosurgery, University of Pittsburgh, Pittsburgh, PA, March 20, 2002. 15. “Non-Alzheimer’s Dementia: Diagnosis and Treatment”, Neurology Grand Rounds, Allegheny

General Hospital, Pittsburgh, PA, March 20, 2002. 16. “Affective Ataxia in an Athyroid Doc”, Combined Neuroscience Conference, University of

Pittsburgh Department of Neurology, December 18, 2001. 17. “Beyond Cognition-Before Dementia”, Psychiatry Grand Rounds, Allegheny General Hospital,

Pittsburgh, PA, November 29, 2001 18. “Lewy Bodies and Dementia”, GRECC Friday Conference Series, University VAMC, Pittsburgh,

PA, October 5, 2001. 19. “Diagnosis and Treatment of Alzheimer’s Disease”, Medicine Grand Rounds, Allegheny General

Hospital, Pittsburgh, PA, October 3, 2001. 20. “Dementia and Lewy bodies”. ADRC Topics at Noon Conference, University of Pittsburgh ADRC,

Pittsburgh, PA, September 20, 2001 21. “Diagnosis and Treatment of Alzheimer’s Disease”. Geriatric Medicine Grand Rounds. UPMC

Shadyside Hospital, Pittsburgh, PA. April 11, 2001. 22. “An Interesting Case (Creutzfeldt-Jacob Disease).” Combined Neuroscience Conference, University

of Pittsburgh Department of Neurology, October 25, 2000. 23. “Mind and Brain: Cholinergic Connections”, Pittsburgh Psychiatric Society, Pittsburgh, PA,

September 18, 2000. 24. “Cholinergic Therapy for Neuropsyhiatric Symptoms in Dementia”, Geriatric Psychiatry Rounds,

Department of Psychiatry, University of Maryland, March 10, 2000. 25. “New Perspectives on the Diagnosis and Treatment of Alzheimer’s Disease”, Department of

Medicine, UPMC Passavant, Pittsburgh, PA, October 26, 1999. 26. “New Perspectives on the Diagnosis and Treatment of Alzheimer’s Disease”, Chairman’s Grand

Rounds, Department of Psychiatry, Wayne State University, Detroit, MI, October 20, 1999. 27. “New Perspectives on the Treatment of Alzheimer’s Disease”, Geriatric Medicine Grand Rounds,

University of Pennsylvania, June 7, 1999. 28. “Calcific Leukoencephalopathy and Cerebral Disconnection”, Combined Neuroscience Grand

Rounds, University of Pittsburgh School of Medicine, March 17, 1999. 29. “New Perspectives on the Diagnosis and Treatment of Alzheimer’s Disease”, Medicine Grand

Rounds, UPMC St. Margaret Hospital, Aspinwall, PA, March 11, 1999.

19

30. “Current Perspectives on the Diagnosis and Treatment of Alzheimer’s Disease”, Medicine Grand Rounds, University of Medicine and Dentistry of New Jersey / Robert Wood Johnson Medical Center, New Brunswick, NJ, February 24, 1999.

31. “New Perspectives on the Treatment of Alzheimer’s Disease”, Neurology Grand Rounds, Temple University School of Medicine, February 19, 1999.

32. “An Unusual Case of Dementia: Does White Matter Matter?”, Combined Neuroscience Grand Rounds, University of Pittsburgh School of Medicine, February 10, 1999.

33. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Medicine Grand Rounds, UPMC McKeesport, January 5, 1999.

34. “Dementia with Lewy Bodies”, discussant, Psychiatry Grand Rounds, Western Psychiatric Institute and Clinic, University of Pittsburgh, October 2, 1998.

35. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Medical Grand Rounds, Medical Center of Beaver, Beaver, PA, October 2, 1998.

36. “Dementia with Lewy Bodies: One Part Alzheimer’s With an Extra Twist of Parkinson’s”, Department of Medicine, Mercy Hospital of Pittsburgh, October 16, 1997.

37. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Department of Medicine, Geisinger Clinic, Danville, PA, September 26, 1997.

38. “Alzheimer’s Therapy: Through the Looking Glass”, Department of Medicine, Eastern Carolina University School of Medicine, Greenville, NC, September 19, 1997.

39. “Alzheimer’s Therapy: Through the Looking Glass”, Department of Psychiatry, John L.Umstead State Mental Hospital, Raleigh, NC, September 18, 1997.

40. “Alzheimer’s Therapy: Through the Looking Glass”, Department of Psychiatry, Duke University Medical Center, Durham, NC, September 18, 1997.

41. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Department of Medicine, United Community Hospital, Grove City, PA, May 21, 1997.

42. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Department of Medicine, Clearfield Hospital, Clearfield, PA, May 15, 1997.

43. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, St. Francis Hospital of Pittsburgh, Department of Medicine, December 6, 1996.

44. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Department of Medicine, Mercy Hospital of Pittsburgh, August 22, 1996.

45. “Alien Hand Syndrome”, Department of Neurology, University of Pittsburgh, March 13, 1996. 46. “Cholinergic System and Behavior in Alzheimer’s Disease”, GRECC, Seattle Veterans Affairs

Medical Center, November 14, 1995. 47. “Alien Hand Syndrome and Apraxia: Clinical, Radiological, and Pathological Features”, UCLA

Department of Neurology, March 21, 1995. 48. “Neuropsychiatric Aspects of Alzheimer’s Disease”, Robert F. Kennedy Medical Center, Hawthorne,

CA, February 9, 1995. 49. “Alzheimer’s Disease and Other Dementias”, Century City Hospital, Century City, CA, March 23,

1994. 50. “Auditory Agnosia”, UCLA Department of Neurology, February 8, 1994. 51. “Alzheimer’s Disease”, Simi Valley Hospital, Simi Valley, CA, February 3, 1994. 52. “Parkinson’s Disease”, Kaiser-Bellflower Hospital, Bellflower, CA, January 26, 1994. 53. “Alzheimer’s Disease and Dementia in the Elderly”, Rio Hondo Hospital, Downey, CA, January 3,

1994 54. “Neurological Aspects of Dementia”, Hollywood Community Hospital, Van Nuys, CA, October 27,

1993.

CONTINUING EDUCATION: University of North Carolina-Chapel Hill:

20

1. “Understanding the Pathophysiology and and Treatment of AD and Other Dementias”, Caring For Patients with Alzheimer’s Disease and other Dementia, UNC School of Nursing, Chapel Hill, NC, October 19, 2012.

2. “Screening for Dementia”, 16th Annual Challenges in Geriatrics Conference, Program on Aging, Chapel Hill, NC, February 12, 2005.

3. “The Reality of Current Clinical Practice” (Panel Moderator), Alzheimer Association workshop on The Cultural Context of Assessment, Diagnosis and Interventions in Diverse Groups of Older People (with dementia), Chapel Hill, NC, April 28-29, 2004.

4. “Dementia Preceptorship” (Director and Presenter), Department of Neurology, Chapel Hill, NC, April 7 and June 9, 2004.

5. “Anticholinesterases for Treating Behavioral Problems in Dementia”. Psychiatry Across the Ages-CME Program. Department of Psychiatry, Chapel Hill, NC, November 21, 2003.

6. “Alzheimer’s Disease and Other Dementias”, Geriatric Continuing Education Conference, School of Nursing, Chapel Hill, NC, October 31, 2003.

7. “Alzheimer’s and Other Dementias”, Medical Alumni Weekend CME Program, Chapel Hill, NC, Department of Neurology, October 17, 2003.

External Sites:

American Academy of Neurology:

1. “Neurobehavioral Assessment” in Case Studies in Behavioral Neurology course (Director and faculty), New Orleans, LA, April 26, 2012.

2. “Neurobehavioral Assessment” in Case Studies in Behavioral Neurology course (Director and faculty), Honolulu, HA, April 15, 2011.

3. “Parkinsonian Dementias”, Non-Alzheimer Dementia course (Director and faculty), Toronto, Canada, April 12, 2010.

4. “Parkinsonian Dementias”, Non-Alzheimer Dementia course (Director and faculty), Seattle, WA, May 1, 2009.

5. “Memory Disorders: Treatment”, Behavioral Neurology: Memory course, Seattle, WA, April 27, 2009.

6. “Parkinsonian Dementias”, Non-Alzheimer Dementia course (Director and faculty), Chicago. IL, April 14, 2008.

7. “Parkinsonian Dementias”, Non-Alzheimer Dementia course (Director and faculty), Boston, MA, May 5, 2007.

8. “Dementia with Lewy Bodies”, Non-Alzheimer Dementia course, San Diego, CA, April 3, 2006. 9. “Role of Psychotropics in Treatment of Behavioral Disorders in Dementia”, Management of

Common Behavioral Disturbances in Dementia course, San Diego, CA, April 2, 2006. 10. “Dementia with Lewy Bodies”, Non-Alzheimer Dementia course, Miami, FL, April 15, 2005. 11. “Dementia with Lewy Bodies”, Non-Alzheimer Dementia course, San Francisco, CA, April 26,

2004. 12. “Dementia with Lewy Bodies”, Non-Alzheimer Dementia course, Honolulu, HI, March 31, 2003. 13. “Dementia and Parkinsonism”, Dementia Update course, Denver, CO, April 14, 2002. 14. “Treatment of Behavioral Symptoms in Alzheimer’s Disease. Dementia Therapy program, San

Diego, CA, May 3, 2000.

Society for Behavioral and Cognitive Neurology Symposium:

1. “Neurobehavioral Issues in Sleep: Mood, Memory and Other Mischief” (Chair and faculty, other faculty: Eric Nofzinger, MD, Robert Stickgold, PhD), Annual Meeting of the American Neuropsychiatric Association, Boston, MA, April 3, 2013.

2. “Autoimmune Encephalopathy”, (Chair and faculty, other faculty: Josep Dalmau, MD. PhD),

21

Annual Meeting of the American Neuropsychiatric Association, New Orleans, LA, March 21, 2012. 3. “Nuts and Bolts of Traumatic Brain Injury: Impact and Outcomes” (Chair, faculty: David

Arciniegas, MD, Christopher Filley), MD, Annual Meeting of the American Neuropsychiatric Association, Denver, CO, March 24, 2011.

4. “Normal-Pressure Hydrocephalus: Taking a Walk Down Memory Lane”, (Chair and faculty, other faculty: Neill Graff-Radford, MD), Annual Meeting of the American Neuropsychiatric Association, Tampa. FL, March 17, 2010.

5. “Getting to Know the Right Anterior Hemisphere: Dominance is More Than Just Talk”, (Chair and faculty, other faculty: Katherine Rankin, PhD, Bud Craig, PhD), Annual Meeting of the American Neuropsychiatric Association, San Antonio, TX, February 19, 2009.

6. “Pain Hurts: Who, What, and Where” (Chair and faculty, other faculty: Robert Coghill, PhD), Society for Behavioral and Cognitive Neurology Workshop, Savannah, GA, March 1, 2008.

7. “Parkinsonian Dementias”, Neuropsychiatry of Subcortical Disorders, Part II. ANPA Workshop, Annual Meeting of the American Neuropsychiatric Association, Tucson, AZ, February 17, 2007.

8. “White Matter Matters” (Chair and faculty, other faculty: Christopher Filley, MD), Annual Meeting of the American Neuropsychiatric Association, Tucson, AZ, February 17, 2007.

9. “The Cerebellum: Moving Beyond The Motor System” (Chair and faculty, other faculty: Jeremy Schmahmann, MD, PhD), Annual Meeting of the American Neuropsychiatric Association, San Diego, CA, February 18, 2006.

10. “Posterior Cortical Atrophy” (Chair and faculty, other faculty: Mario Mendez, MD, PhD, Andrew Kertesz, MD), Annual Meeting of the American Neuropsychiatric Association, Bal Harbour, FL, February 26, 2005.

11. “Glutamate in Cognitive Neuropsychiatry” (Chair and faculty, other faculty: Michael Rogawski, MD, PhD), Annual Meeting of the American Neuropsychiatric Association, Bal Harbour, FL, March 6, 2004.

12. “Pharmacology of Cognition” (Chair and presenter), Annual Meeting of the American Neuropsychiatric Association, Honolulu, HA, February 6, 2003.

13. “Neuropsychiatric Aspects of Dementia”, Fundamentals of Neuropsychiatry course, American Neuropsychiatric Association, February 3, 1999, New Orleans, LA.

Regional Neurology Meetings:

1. “Long-Term Consequences: MCI, Dementia, and Chronic Traumatic Encephalopathy,” UNC Matthew Gfeller Center Sport-Related Neurotrauma Symposium, April 30, 2011.

2. “Clinical and Cognitive Assessment and Managing Behavior in Alzheimer’s Disease and Lewy Body Disease,” Dementia Spectrum: Southeastern Medical Conference, Concord, NC, March 15, 2008.

3. “Diagnosis, Symptoms and Medication Management and Non Drug Therapy in Alzheimer’s and Lewy Body Disease,” Dementia Spectrum: Southeastern Medical Conference, Concord, NC, March 14, 2008.

4. “Alzheimer’s Disease: Overview,” Current Therapy in Neurology 2007: Parkinson’s, Alzheimer’s, and Multiple Sclerosis, Atlanta, GA, August 24, 2007.

5. “Alzheimer’s Disease: Future Therapies,” Current Therapy in Neurology 2007: Parkinson’s, Alzheimer’s, and Multiple Sclerosis, Atlanta, GA, August 24, 2007.

6. “Considering the Pathophysiology of PD Dementia,”, Satellite Symposium “Cholinergic Implications in Parkinson’s Disease-Related Dementia: Treating Cognitive Decline in a Motor Disorder”, American Association of Geriatric Psychiatry, New Orleans, LA, February 7, 2007.

7. “Cerebellar Disorders and Cognition”, 29th Annual Contemporary Clinical Neurology Symposium, Vanderbilt Department of Neurology, Hilton Head, SC, July 20, 2006.

8. “Vascular Dementia”, 29th Annual Contemporary Clinical Neurology Symposium, Vanderbilt Department of Neurology, Hilton Head, SC, July 20, 2006.

22

9. “Neurobehavioral Aspects of Alzheimer’s Disease”, 29th Annual Contemporary Clinical Neurology Symposium, Vanderbilt Department of Neurology, Hilton Head, SC, July 20, 2006.

10. “Parkinson-Related Dementias”, 29th Annual Contemporary Clinical Neurology Symposium, Vanderbilt Department of Neurology, Hilton Head, SC, July 20, 2006.

11. “Treatment Issues in Dementia”, Practical Issues in Neurology, Department of Neurology, Vanderbilt University, Nashville, TN, February 28, 2004.

12. “Diagnostic Issues in Dementia”, Practical Issues in Neurology course, Department of Neurology, Vanderbilt University, Nashville, TN, February 28, 2004.

13. “Diagnosis and Treatment of Dementia”, Update in Neurology, Southern Clinical Neurology Association, Orlando, FL, May 25, 2002.

14. “Alternative Treatments for Alzheimer’s Disease”. 29th Annual Meeting of the Southern Clinical Neurology Association, Puerto Vallarta, Mexico, January 22, 2002.

15. “Frontotemporal, Vascular, and Mixed Dementias: Diagnosis and Treatment”. 29th Annual Meeting of the Southern Clinical Neurology Association, Puerto Vallarta, Mexico, January 22, 2002.

16. “New Perspectives on Alzheimer’s Disease”, Annual Meeting of the Neurological Society of New Jersey, Iselin, NJ, November 18, 1998.

17. “Cholinergic - Monoaminergic Approaches to Dementia”, Advances in the Social Brain Workshop, co-sponsored by the John Douglas French Foundation for Alzheimer’s Research and Cure Autism Now Foundation, Marina del Ray, CA, October 24, 1997.

18. “Noncognitive Behavioral Disturbances in Alzheimer’s Disease”, 16th Annual Army Department of Medicine Neurology Course, Tacoma, WA, November 23, 1996.

Internet Video Presentation:

• “Role of Physicians in Working With Caregivers: Resources and Guidelines” (video-lecture), Quality of Life in Dementia: Physician and Caregiver CME course, Prous Science, Timely Topics in Medicine-Dementia, 2004.

CME Videoconference Presentations: • “Alzheimer’s Disease: Burden and Therapy”, University of South Dakota School of Medicine,

Distance Learning Network, St. Louis, MO, November 15, 2001.

• “Burden and Care in Alzheimer’s Disease”. Clinical Advances in Patient Care: Multiple-Domain Treatment of Alzheimer’s Disease. The Baron Gibson Foundation / University of Wisconsin, HBO Studios, New York, NY, July 11, 2001.

Radio:

• “Frontotemporal Degeneration,” Caring Connections, Nicole Bruno, host, WCHL 97.9 FM, Durham, NC, April 28, 2013.

Television:

• “Imaging technology can help diagnose, treat brain diseases,” WRAL-TV, May 25, 2012. http://www.wral.com/lifestyles/healthteam/story/11136514/

• North Carolina People (William C. Friday, Host) UNC-TV, June 2, 2006.

Newspaper:

23

• “When Both Parents Suffer Dementia, Children Believe it is in Their Future.”, Denise Grady, New York Times, December 26, 2007.

General Medical:

1. “Benefit of Early Detection,” American Geriatrics Society Satellite Symposium: Dementia Screening and Early Detection: What Do We Know About It and Is It a Good Idea? Grapevine, TX, May 2, 2013.

2. “Dementia: New Techniques in Screening and Diagnosis,” Emerging Issues in Chronic Disease in Primary Care, North Carolina Network Consortium, Greensboro, NC, March 24, 2012.

3. “Alzheimer’s and Related Dementias: Emerging Diagnostic Tools and Therapeutic Strategies”, Innovations in Dementia Screening, Diagnosis, and Management for Aging Service Providers, Carolina Alzheimer’s Network, Greensboro, NC, March 24, 2012.

4. “Dementia Overview: Cognitive Screening, Clinical Assessment, and Differential Diagnosis,” Dementia Advanced Skills Training in Primary Care, Carolina Alzheimer’s Network, Greensboro, NC, March 24, 2012.

5. “Dementia Overview: Cognitive Screening, Clinical Assessment, and Differential Diagnosis,” Dementia Advanced Skills Training in Primary Care, Carolina Alzheimer’s Network, Greensboro, NC, March 3, 2012.

6. “Dementia Bootcamp”, Chapel Hill Internal Medicine, Triangle Physician Network, January 30, 2012.

7. “Alzheimer’s Disease in the New Millenium”, 10th Annual Geriatric Symposium, Columbia SC, February 5, 2011.

8. “Update in the Diagnosis and Treatment of Alzheimer’s Disease”, 5th Annual Caregiver Education Conference, Williamston, NC, October 16, 2008.

9. “Agitation & Dementia: How to Weigh the Risks & Benefits of Pharmacological Intervention,” Cherry Hospital Mental Health Symposium, Wrightsville Beach, NC, August 18, 2007.

10. “Behavior Is As Behavior Does: An Existential Approach to Dementia,” Keynote address, 10th Annual Alzheimer’s Conference “Alzheimer’s: Who Am I and What’s My Story”, Black Mountain Center, NC, August 3, 2007.

11. “Differential Diagnosis of Dementia,” The Hidden Condition for African Americans: Memory Loss, Eastern North Carolina Alzheimer Association, Durham, NC, April 21, 2007.

12. “Diagnosing and Managing Alzheimer’s and Other Dementias,” Cherry Hospital, Goldsboro, NC, March 19, 2007.

13. “Preventing, Diagnosing, and Managing Dementia and Alzheimer’s”, Geriatric Health Issues Symposium, Danville Regional Medical Center, Danville, VA, November 16, 2006.

14. “Dementia Care—Why Should You?”, North Carolina Academy of Family Physicians “Update in Dementia”, Neurology for the Non-Neurologist, Coastal AHEC, Wilmington, NC, May 14, 2005.

15. “Update in the Diagnosis and Treatment of Dementia”, Beaver County Medical Society, Beaver, PA, November 14, 2002.

16. “Dementia Winter Family Physicians Weekend, Asheville, NC, December 3, 2005. 17. “Behavioral Symptoms in Dementia” workshop, 1st Annual Carolina Regional Alzheimer’s

Conference, Myrtle Beach, SC, November 5, 2004. 18. “Dementia and Mild Cognitive Impairment,”16th Annual Meeting of the Pennsylvania Society of

Physician’s Assistants, Pittsburgh, PA, September 25, 2002. 19. “Alzheimer’s Disease in Perspective: The Increasing Burden of Care”. State of the Art: Effective

Management of Dementia. Satellite symposium, American College of Physicians-American Society of Internal Medicine, Philadelphia, PA, April 11, 2002.

24

20. “Issues of Patient Care; Long-term Care vs. Long-term Benefit”. Complete Care: Successful Strategies in the Management of Dementia”. Satellite symposium, 16th Annual Meeting of the American Association of Geriatric Psychiatry, Orlando, Florida, February 25, 2002.

21. “Diagnosis and Treatment of Alzheimer’s Disease”. National Academy of Family Practitioners, Allegheny Chapter. Pittsburgh, PA. February 17, 2002.

22. “Specific Pharmacological Management of Alzheimer’s Disease”. Managing the Stages of Alzheimer’s Disease. 95th Annual Meeting of the Southern Medical Association, Nashville, TN, November 8, 2001.

23. “Alzheimer’s Disease: Present, Future, and What to Do in Between”. South Central PA Aging and Health Education Council, Altoona, PA, October 4, 2001

24. “Alzheimer’s Disease: Burden and Therapy”. Advances in Patient Management: New Treatment Options for Alzheimer’s Disease. Satellite symposium, Annual Meeting of the American Academy of Physician’s Assistants, Anaheim, CA, May 26, 2001.

25. “Alzheimer’s Disease: Cognition, Behavior, and Function”. Advances in Patient Management: New Treatment Options for Alzheimer’s Disease. Satellite symposium, 33rd Annual Meeting of the American Academy of Neuroscience Nurses, San Francisco, CA, April 23, 2001.

26. “Communicating Skills: How to Maximize the Exchange of Information with the AD Patient and Caregiver”, AD Summit: Optimizing Management of Alzheimer’s Disease in Clinical Practice”, Cincinnati, Ohio, October 27, 2000.

27. “Principles of Alzheimer’s Management”, AD Summit: Optimizing Management of Alzheimer’s Disease in Clinical Practice”, Cincinnati, Ohio, October 27, 2000.

28. “Is it Mild Cognitive Impairment or Alzheimer’s Disease: How to Tell the Difference”, Annual Meeting of the Pennsylvania Association of Physician’s Assistants, Harrisburg, PA, October 13, 2000.

29. “Current Diagnosis and Treatment of Alzheimer’s Disease”, Annual Meeting of the New Jersey Geriatric Society, Atlantic City, NJ, February 10, 2000.

30. “Response of Neuropsychiatric Symptoms to Cholinergic Therapy”, Diagnostiche und therapeutische Herausforderungen bei Alzheimer Krankheit, Aricept Specialist Symposium, Dresden, Germany, October 30, 1999.

31. “Differential Diagnosis and Treatment of Alzheimer’s Disease”, Diagnostiche und therapeutische Herausforderungen bei Alzheiemer Krankheit, Aricept Specialist Symposium, Dresden, Germany, October 30, 1999.

32. “The Man Who Mistook His Wife For a Hat: Visual Agnosia and Other Disorders of Perception”, Neurology in Primary Care, University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences, Pittsburgh, PA, October 16, 1999.

33. “Memory Disorders in Clinical Practice”, Neurology in Primary Care, University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences, Pittsburgh, PA, October 16, 1999.

34. “Normal Aging or Early Signs of Alzheimer’s Disease: How to Tell the Difference?” (two sessions), Late-Life Depression and Dementia: Opportunities for the New Millenium, University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences, Pittsburgh, PA, October 15, 1999.

35. New Perspectives on the Treatment of Alzheimer’s Disease”, Plenary Address, 116th Annual Meeting of the Kentucky Medical Association, Lexington, Kentucky, September 29, 1999.

36. “Diagnosis and Treatment of Alzheimer’s Disease”, Section of Geriatric Medicine, 116th Annual Meeting of the Kentucky Medical Association, Lexington, Kentucky, September 29, 1999.

37. “Dementia Diagnosis and Treatment”, Neurology and Psychiatry in Primary Care, UMDNJ School of Osteopathic Medicine, Ocean City, NJ, August 19, 1999.

38. “Response of Neuropsychiatric Symptoms to Cholinergic Therapy”, Diagnostiche und therapeutische Herausforderungen bei Alzheiemer Krankheit, Aricept Specialist Symposium, Cologne, Germany, July 3, 1999.

25

39. “New Perspectives on Alzheimer’s Disease”, Third Annual Geriatric Neuroscience Symposium, Johnstown-Willis Hospital, Richmond, VA, May 14, 1999.

40. “Alzheimer’s Disease in Clinical Practice”, Beaver County Chapter, Pennsylvania Academy of Family Physicians, Beaver, PA, April 29, 1999.

41. “Cholinergic Therapy of Behavioral Disturbances in AD”, Pfizer Norway Symposium for Specialists, Oslo, Norway, April 24, 1999.

42. “Lunch with the Professor: Dementia”, Update in Internal Medicine Course, University of Pittsburgh School of Medicine, Pittsburgh, PA, November 5, 1998.

43. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, First Annual Conference on Behavioral Health in the Elderly, sponsored by Brownsville General Hospital, Nemacolin Country Club, Centerville, PA, October 29, 1998.

44. Alzheimer’s Disease: Research and Therapeutic Advances. Program Moderator, Co-sponsored by Pragmaton and the Eastern Pennsylvania Chapter of the Alzheimer’s Association, Philadelphia, PA, April 2, 1998.

45. Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Geriatrics Symposium, UPMC Southside, March 25, 1998.

46. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Annual Refresher Course for Western Pennsylvania Osteopathic Physicians, Hidden Valley Resort, Somerset, PA, January 15, 1998.

47. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Annual Meeting of the Lawrence County Medical Society, New Castle, PA, June 11, 1997.

48. “Diagnosis and Treatment of Alzheimer’s Disease”, Update in Internal Medicine: Practical Approaches to Common Medical Problems, University of Pittsburgh School of Medicine, Pittsburgh, PA, November 14, 1997.

49. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, 38th Annual Western PA Refresher Course, Clearfield, PA, September 12, 1997.

50. “Cognitive and Behavioral Aspects of Alzheimer’s Disease”, Intervening in Alzheimer’s Disease, University of Illinois-Chicago, November 15, 1996.

51. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Update in Internal Medicine: Practice in the New Health Care Environment, University of Pittsburgh School of Medicine, Pittsburgh, PA, October 31, 1996.

52. “Behavioral Management of Alzheimer’s Disease Patients”, Current Concepts in Managing the Alzheimer’s Disease Patient, New York Medical College/Westchester County Medical Center, Valhalla, NY, May 21, 1996.

53. “Alzheimer’s Disease Update”, Common Problems in Geriatric Patients, Monongahela Valley Hospital, October 18, 1995.

Community Outreach:

1. “Diagnosing Dementia: Taking A look Backward To Move Forward” 10th Annual Wilson Caregiver Education Conference, Barton College, Wilson, NC, March 5, 2013.

2. “Frontotemporal Degeneration: Improving Outcomes and Outreach”. Keynote address, 2nd Annual Triangle Caregiver Conference, Raleigh , NC, July 26 2012, co-sponsored by the Association for Frontotemporal Degeneration and Alzheimers North Carolina.

3. “Alzheimer’s “FTD Update”, “Alzheimer NC FTD Support Group, Chapel Hill, NC, March 4, 2012. 4. “State of the Art Diagnosis of Dementia”, 6th Annual Outer Banks Caregiver Education Conference,

Alzheimer North Carolina, Kill Devil Hills, NC, January 23, 2012. 5. “Diagnosing Dementia: State of the Art and Emerging Science”, 8th Annual Caregiver Education

Conference, Alzheimer North Carolina, Lumberton, NC, November 17, 2011. 6. “Non-Alzheimer’s Dementias”, Caregiver Education Conference, African-Americans & Alzheimer

Disease, North Carolina A&T State University, November 12, 2011.

26

7. “Frontotemporal Degeneration: Translating Research Into Practice”. Keynote address, !st Annual Triangle Caregiver Conference (co-sponsored by the Association for Frontotemporal Degeneration). Raleigh, NC, July 12, 2011.

8. “The Importance of Early Diagnosis: Managing Expectations”, 24th Annual Bryan Alzheimer’s Disease Research Center Conference, Duke University Medical Center, Durham, NC, February 18, 2010.

9. “The Other Dementias”, 2009 Estes Express Conference on Dementia, Greater Richmond Alzheimer’s Association chapter, Richmond, VA, November 4, 2009.

10. “Profiles in Dementia: Research Update”, The Many Faces of Dementia 2009. 16th Annual Spring Education Conference, Western Carolina Alzheimer’s Association, Charlotte, NC, March 19, 2009.

11. “Many Faces of Dementia,” UNC Mini-Medical School, Chapel Hill, NC, March 18, 2008. 12. “Lewy Body Dementias: What To Know, What To Do.”, 14th Annual Alzheimer Association

Dementia Care Conference, Atlanta, GA, September 11, 2006. 13. Lewy Body Dementias: Promise and Progress”. Lewy Body Dementia Association Caregiver

Conference, Atlanta, GA, September 10, 2006. 14. “Non-Alzheimer’s Dementia”, 1st Annual Carolina Regional Alzheimer’s Conference, Myrtle Beach,

SC, November 5, 2004. 15. “Non-Alzheimer’s Dementia”, Alzheimer’s 2005: Imagine the Future, 19th Annual Bryan

Alzheimer’s Disease Research Center Conference, Duke University Medical Center, Durham, NC, February 10, 2005.

16. “Non-Alzheimer’s Dementia”, 1st Annual Carolina Regional Alzheimer’s Conference, Myrtle Beach, SC, November 5, 2004.

17. “Alzheimer’s Disease and Beyond: New Frontiers in Dementia”, Keynote address, 20th Annual Caregiver Education Conference of the Western Carolina Alzheimer Association/Mountain Region Office and Mountain AHEC, Black Mountain, NC, November 4, 2004.

18. “The Many Faces of Dementia”, Keynote address, Annual Caregiver Conference of the Western Carolina Alzheimer Association, Charlotte, NC, March 11, 2004.

19. “Managing Cognitive and Behavioral Symptoms in Alzheimer’s Disease”. Alzheimer’s Disease Update: Aging Demographics and the Race Against Time. 28th Annual Meeting of the Association for Gerontology in Higher Education, Pittsburgh, PA, March 2, 2002.

20. “Alzheimer’s Disease: Medical and Scientific Update”. Alzheimer’s Disease Update: Aging Demographics and the Race Against Time. 28th Annual Meeting of the Association for Gerontology in Higher Education, Pittsburgh, PA, March 2, 2002.

21. “Alzheimer’s Disease: Medical and Scientific Update”. 3rd Annual Conference on Early-Stage Alzheimer’s Disease, New York City Chapter of the Alzheimer’s Association, New York, NY, December 7, 2001.

22. “Understanding Alzheimer’s Disease”. Alzheimer’s Disease Caregiver Symposium: What Every Caregiver Needs to Know, Atlanta, GA, November 10, 2001.

23. “Differential Diagnosis of Dementia”. Late-Life Depression and Dementia: Is it Time for Prevention? Western Psychiatric Institute and Clinics, University of Pittsburgh School of Medicine, Pittsburgh, PA, October 19, 2001.

24. “Alzheimer’s Disease: Burden and Care” (physicians); “Practical Solutions for Caregivers: Mastering the Caregiver Challenge”, and “Communication Skills Workshop” (caregivers), Alzheimer’s Disease Caregiver Symposium: What Every Caregiver Needs to Know, Cleveland, OH, September 8, 2001.

25. “How Close Are We to Curing—or Preventing—Alzheimer’s Disease?”, Cambria-Somerset Council Conference on Aging, Seven Springs, PA, September 15, 2000

26. “Alzheimer’s Caregiver Seminar”, ManorCare Health Services, South Hills Country Club, Pittsburgh, PA, June 17, 1999.

27. “Advances in the Diagnosis and Treatment of Alzheimer’s Disease”, Keynote Address, Ninth Annual Seminar of the Northeast Pennsylvania Chapter of the Alzheimer’s Association, Wilkes

27

University, Wilkes-Barre, PA, June 5, 1997. 28. “Alzheimer’s Disease: Medication Management”. Alzheimer’s Disease and Dementia Conference

for Family and Professional Caregivers, Vintage Community Adult Day Care Center, Pittsburgh, PA, November 4, 1995.

Clinical Trial Investigator Training Presentations:

1. “Neuropsychiatric Inventory” and “Alzheimer Disease Cooperative Study-Activities of Daily Living (severe)”, Memantine in Moderate to Severe Alzheimer’s Disease (MEM-50) Investigator’s Meeting, Orlando, FL, May 19, 2005.

2. “Neuropsychiatric Inventory-Nursing Home Version” and “Assessing Agitation in the Nursing Home”, Memantine in Moderate to Severe Alzheimer’s Disease (MEM-22) Investigator’s Meeting, Orlando, FL, October 7, 2004.

3. “CSINAPS (Circadian Sleep Inventory for Normal and Pathological Seniors)”, Alzheimer’s Disease Cooperative Study group, Melatonin in Alzheimer’s disease study, Portland, Oregon, June 8, 1997.

4. “The Neuropsychiatric Inventory”, Alzheimer’s Family Care Program, Parke-Davis, Baltimore, MD, June 4, 1996.

5. “The Neuropsychiatric Inventory”, Metrifonate Phase III Trial, Bayer Pharmaceuticals, Chicago, IL, May 14, 1996.

6. “The Neuropsychiatric Inventory”, CONTACT Investigator’s Meeting, Parke-Davis, San Diego, CA, January 20, 1996.

7. “The Neuropsychiatric Inventory”, CONTACT Investigator’s Meeting, Parke-Davis, Miami, FL, January 13, 1996.

8. “The Neuropsychiatric Inventory”, Metrifonate Phase III Trial, Bayer Pharmaceuticals, Chicago, IL, October 8, 1995.

9. “The Neuropsychiatric Inventory”, Milameline Phase III Trial, Parke-Davis, New Orleans, LA, July 27, 1995.

GRANTS/CONTRACTS:

Pending:

NIA R21 (K. Giovanello, PI) Functional Brain Network Abnormalities in MCI: Effects of Memory Performance. Role: Co-Investigator

National Football League Player’s Association 8/1/2013 – 2/28/2014 Multidisciplinary Brain Injury/Concussion Treatment Program for NFl Players This grant will support a multidisciplinary program for the comprehensive diagnosis and management of cognitive, behavioral, and musculo-skeletal disorders in retired National Football League players at UNC-Chapel Hill and two satellite sites (U. of Virginia and NorthShore Neurological Institute).

Role: Director, Cognitive Neurology (K. Guskiewicz, PI, Michael Lee, Co-PI)

UNC Biomedical Research Imaging Center 11/1/12 – 10/31/13 Pilot Study Examining Structural and Functional MRI Imaging in Frontotemporal Degeneration. The purpose of this pilot study is to examine structural and functional MRI imaging correlates of social cognition measures in subjects with behavioral variant Frontotemporal Degeneration. This study is also a companion study to IRB 12-1372: “MRI Imaging Database for Frontotemporal

28

Degeneration: A Pilot Feasibility Study.” Role: PI NIA 1R01AG041721 (D. Shen, PI) 8/1/2012 - 5/31/2015 Quantifying Brain Abnormality by Multimodality Neuroimage Analysis $413,404 This grant project will employ multiple regression statistical methodology to develop a high-level quantitative analytical platform for detecting quantitative individual differences in brain pathology.

Role: Co-Investigator NIDCR 1K23DE022470 (X. Chen, PI) 9/1/2012 – 8/31/2017 Development and Validation of An Instrument to Assess Cognitive Function Regulating Dental Care In Cognitively Impaired Elderly $128,287

This career development award will allow the candidate to become an independent researcher in the development of cognitive assessments that will allow dentists to identify individuals with cognitive impairment who may require adaptive training in maintaining dental hygiene. Role: Co-Mentor NCCAM 2 T32 AT003378 06 (S. Gaylord, J.D. Mann, Co-PIs) 3/15/2012 – 3/14/2017 UNC Research Fellowship in Complementary and Alternative Medicine $318,397 The goal of the UNC Complementary and Alternative Medicine (CAM) Research Training Program

(CRTP) is to cultivate well-trained, independent researchers for leadership in investigating efficacy, effectiveness, safety and mechanisms of action of CAM therapies.

Role: Co-Investigator / Mentor NIBIB 1R01EB009634 (D. Shen, PI) 12/01/2009 - 11/30/2013 Fast, Robust Analysis of Large Population Data $250,000 This project aims at development, testing, and evaluation of fast, robust, and accurate group

registration and statistical comparison algorithms for effective processing of large sets of brain images simultaneously, thus enabling the detection of tiny, complex group differences.

Role: Co-Investigator Guardian Angel Thrift Fund / Alzheimer North Carolina 7/1/2012 – 6/31/2013 Optimizing the Assessment of Neuropsychiatric Symptoms in Clinical Practice $48,500 This project will validate an expanded form of the Neuropsychiatric Inventory – Questionnaire (NPI-Q2) that includes specific itemized behaviors for each of 12 symptom domains with the standard NPI, and evaluate the NPI-Q2 Depression scale as a screen for depression. Achieving both aims will support use of the NPI-Q2 as a measure for quality standards in dementia care. Role: PI

TauRx Therapeutics 9/1/2012 – 8/30/2015 A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD). Role: Site PI

United States Administration on Aging (P. Sloane, PI) 8/2010 - 3/2013 Randomized Trial of University-AAA-State Partnership to Link Primary Care Physicians and Aging Service Providers in the Support of Persons with Alzheimer’s Disease and

Related Disorders. $504,250

29

This study will conduct a randomized controlled trial of a dementia educational intervention on physicians participating in the Carolina Alzheimer’s Network to evaluate the potential utility and quality improvement for dementia care. Role: Co-Investigator Martek Biosciences (K. Guskiewicz, PI) 5/1/2008 – 3/31/2013 Docosahexaenoic Acid (DHA) Supplementation in Retired Professional Football Players This is a randomized placebo-controlled parallel group study of DHA supplementation in retired professional football players. Role: Co-Investigator NIA K01-AG028774 (K. Giovanello, PI) 6/13/2007 – 6/23/2013 Functional-Anatomic Correlates of Relational Memory in Aging and MCI This career development award will entail a training and research program aimed at investigating associative memory and its functional neural substrates in normal and mild cognitively impaired elderly subjects. Role: Co-Investigator

American Urogynecologic Society Foundation (E. Geller, PI) 3/1/2013 – 2/28/14 The Effect of Anticholinergics on Cognitive Function in the Elderly: a Randomized Controlled Trial. This randomized controlled study will evaluate the clinical benefits of an anticholinergic medication used to treat bladder overactivity in relation to potential adverse cognitive side effects. Data from this pilot trial will be used for a larger study that will lead to the development of a clinical measure for evaluating the risk/benefit of medications used to treat bladder dysfunction. Role: Co-Investigator

Completed

The Duke Endowment (P. Sloane, PI) 7/1/2008 – 12/30/2012 Carolina Alzheimer’s Network $540,491

This grant will expand the UNC Memory Disorders Clinic and train North Carolina primary care physicians in the diagnosis and treatment of dementia.

Role: Co-PI (20% effort) NC TraCS CDW-H Grant 5/1/2011 – 4/30/2012 Collaborative Dementia Database Development (P. Sloane, PI)

This pilot study will examine dementia diagnostic coding at different clinical sites across two healthcare systems (UNC Healthcare and Carolinas Medical Center) and evaluate clinical data collected in light of recently published quality standards for dementia care. These data will pave the way for developing a standardized set of dementia diagnostic criteria for the healthcare system to f acilitate adherence to quality standards and database research. $50,000 Role: Co-PI

Allon Pharnaceuticals, Inc. 11/1/2010 – 1/31/2013 AL-108-231 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the

Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. $78,000 This 52-week study will evaluate the safety and efficacy of an anti-tau protein aggregant compound

on subjects with progressive supranuclear palsy. Role: Site PI

30

Forest Research Institute (A.Boxer, PI) 9/2007 - 8/2012 A prospective, randomized, multi-center, double-blind, 26 week, placebo-controlled trial of memantine (10mg BID) for the frontal and temporal subtypes of Frontotemporal Dementia. $161,000 This study is a multicenter randomized placebo-controlled double-blind study of memantine at 10

mg bid evaluating its safety and efficacy for treating behavioral symptoms in FTD. Role: Site PI

NC TraCS (K. Giovanello, PI) 4/1/2011 – 3/31/2012 Large-scale functional brain network abnormalities in Mild Cognitive Impairment. NC TRACS 50K Pilot Study. $50,000

Role: Co-investigator

NC TraCS (J. Piven, PI) 4/1/2011 – 3/31/2012 Autism in Older Adults: A Pilot, Descriptive Study. NC TRACS 50K Pilot Study. $50,000

Role: Co-investigator NIH R21 (H. Zhu PI) 1/2009-2/2011 Longitudinal Analysis of Biomedical Imaging Data $183,419 The purpose of this study is to develop and validate MRI imaging methods for quantitative longitudinal analyses in dementia. Role: Co-investigator (3%) Guardian Angel Fund 8./09 – 12/10

Assessing Longitudinal Change in Clinical Practice $50,000 This study will validate a global clinical outcome measure for dementia patients in clinical practice settings, compare the relative sensitivity to change between the standard and an extended form of the MMSE, and validate a novel memory awareness scale as part of the HVLT. Role: PI (5%) AHRQ (ARRA) 3/2010 -5/2010 Mental Health and Substance Abuse Issues Exploration Forum (D. Jonas, PI) The purpose of this grant is to identify areas for comparative effectiveness research in mental health and Alzheimer’s disease. Role: Co-Investigator

U.S. Administration on Aging (P. Sloane PI) 1/01/2009 – 6/30/2010 Strengthening the Linkages Between Primary Care Medical Providers and Aging Service Programs This project will establish a partnership between a newly funded, university-based statewide network of education and support for medical providers and the NC state aging services network. $301,672

Role: Co-Investigator (3%) Eastern North Carolina Alzheimer’s Association/Guardian Angel Fund 1/2006 – 6/2008 Dementia Tool-Kit: Development and Validation $125,000 This study will support continued development, validation, and implementation of clinical assessment tools to facilitate dementia screening, diagnosis, and evaluating therapeutic outcomes in community care settings. Role: PI (20% effort) Georgetown Univeristy / National Institute on Aging 5/2005 – 8/2008 A Multicenter Study of Huperzine A for the Treatment of Mild to Moderate Alzheimer’s Disease. $84,000

31

This Phase II/III clinical trial is funded by the National Institute on Aging (Paul Aisen, PI, Georgetown University) and is being conducted under the supervision of the Alzheimer Disease Cooperative Study group to evaluate the safety and efficacy of huperzine A, a Chinese herbal remedy, for treating patients with mild to moderate Alzheimer’s disease.

Role: Site PI (10% effort) Janssen Research Foundation 10/2004 – 9/2007 Galantamine in Subjects With Post-Stroke Nonfluent Aphasia $42,000 This study will examine the safety and efficacy of galantamine treatment on language disturbances in subjects with stroke-related aphasia. Role: Co-PI (5% effort) Janssen Research Foundation 4/2005 – 12/2005 MDS-COGS: A Validation Study in Assisted Living This study will examine the sensitivity and specificity of the MDS-COGS, part of the mandated Minimum Data Set, as a screen for dementia in assisted living facilities. Role: Co-Investigator P 50 AG05128-21 Schmechel (PI) 6/2004-10/2005 NIA Pilot Study Cognitive Phenotyping of Parkinsonian Dementias $30,000 This pilot study will examine the utility of combining genetic information and a novel assessment for verbal episodic memory in distinguishing AD from Parkinsonian dementia. Role: PI 5 P50 AG05133-18 DeKosky (PI) 6/1/2000-3/31/2005 NIA Center Project Bohnen (PI) Clinical and Therapeutic Correlates of AChE Imaging in Alzheimer’s Disease This study will examine the therapeutic correlates of donepezil treatment in Alzheimer’s disease subjects using in vivo PET AChE imaging. Role: Co-Investigator PIND Seed Grant Fiez (PI) 6/1/02- 5/31/03 Pittsburgh Institute for Neurodegenerative Disease The Biological Basis of Incremental Learning in Parkinson’s Disease Using fMRI. This study will investigate the neural substrates of reward processing in subjects with Parkinson’s disease before and during manipulation of pre- and post-synaptic dopaminergic receptors. Role: Co-Investigator M1999-0075 Kaufer (PI) 10/30/00-10/29/02 The Pittsburgh Foundation $65,000 Clinical and Therapeutic Correlates of in vivo PET AChE Imaging in Parkinsonian Dementia The study will use the technique of in vivo PET AChE imaging in conjunction with a treatment study using an AChE-inhibitor approved for use in Alzheimer disease to investigate the clinical and therapeutic correlates of cholinergic dysfunction in Parkinsonian dementia. Role: PI Pfizer, Inc. Kaufer (PI) 7/01/99-6/30/02 A Double-Blind, Placebo-Controlled Study of Donepezil in Parkinsonian Dementia $45,000 This study will investigate the clinical safety and efficacy of donepezil in subjects with Parkinsonian dementia. Role: PI

32

5 RO1 AG13672-05 Kamboh (PI) 5/29/96-4/30/02 Risk Genes in Alzheimer’s Disease The proposed studies will delineate several candidate genes in refining and defining the role of genes in determining the risk and natural history of Alzheimer’s disease. Role: Co-Investigator ADRC Seed Money Grant (5 P50 AG05133-18) 4/30/96 – 4/1/98 Sleep and Circadian Disturbances in Alzheimer’s Disease $20,000 This pilot study will develop and perform preliminary validation studies on a clinical assessment of sleep disturbances of patients with dementia. Role: PI 5 P50 AG05133-18 DeKosky (PI) 3/31/95-5/31/00, 6/1/00-3/31/05 ADRC Clinical Core The clinical core will perform clinical and research evaluations at the study entry and at annual follow-up of patients with AD and related dementias and control subject participants in the ADRC. Role: Co-Investigator

PROFESSIONAL SERVICE: COMMITTEES / ORGANIZATIONAL AFFILIATIONS:

2009- Board of Directors, Alzheimer’s North Carolina. 2009-2011 Board of Directors, United Council for Neurologic Subspecialties. 2009-2011 Mental Health Steering Committee, National Quality Forum. 2009-2010 Consultant / Peer Reviewer, Preventing Alzheimer’s Disease and Cognitive Decline,

evidence report for Agency for Healthcare Research and Quality, Duke Evidence-Based Practice Center.

2008- Co-Director, Carolina Alzheimer’s Network 2006-2009 Board of Directors, Eastern North Carolina Chapter of the Alzheimer Association. 2006- Scientific Advisory Council, Lewy Body Dementia Association, Atlanta, GA. 2005- Behavioral Neurology & Neuropsychiatry Certification Examination Committee, United

Council of Neurological Specialties. 2005-2009 Member, Apathy and DSM-V Working Group. 2005-2009 Contributor, Faculty of Medicine 1000, Cognitive Neurology / Dementia. 2005-2009 Consultant, Clinical Tools, Inc., for National Institute on Aging-funded website

(DementiaCareCentral.com) serving dementia caregivers. 2004-2009 Member, Oversight Committee for Diversity, Social and Behavioral Research, National

Alzheimer’s Association, Chicago, IL. 2004-2009 Chair, Data Safety and Monitoring Board, Transdermal Nicotine Treatment of MCI study

(RO1 AG022462, Paul Newhouse, MD, Principal Investigator). 2003- Chair, Society for Behavioral and Cognitive Neurology Symposium, Annual meeting of the

American Neuropsychiatric Association.

PROFESSIONAL SOCIETIES: American Academy of Neurology:

Geriatric Neurology section, 1992-present:

- Clinical Practice Committee, 2000-2001

33

Behavioral Neurology section, 1994-present:

- Project Leader, Evidence-based review of clinical neurobehavioral testing, AAN Behavioral Neurology section, 2012- - Coding and Reimbursement Representative, 2008-2011. - Chair, 2007-2009. - Chair-elect, 2005-2007. - Secretary-Treasurer, 2003-2005. - Education Committee, 1999-2005. - Executive Committee, 1998-present. Society for Behavioral and Cognitive Neurology:

- Past-President, 2009-present - President, 2007-2009. - President-Elect, 2005-2007. - Secretary-Treasurer, 2003-2005. - Head, Education Committee, 2001-2003. - Head, Committee for Internal Certification, 1996-2001. American Neuropsychiatric Association:

- Executive Committee, SBCN Liaison, 2005-present. - Scientific Program Committee, 2005-present - Research Committee, 1997-2008. - Behavioral Neurology Society Liaison, Education Committee, 1997-2001. - Head, Task Force for Internal Certification, 1996-2000. AD HOC JOURNAL REVIEWER: (2011-2 in bold)

1. Aging Health (Future Medicine LTD) 2. Alzheimer’s & Dementia 3. Alzheimer’s Disease and Associated Disorders 4. American Journal of Psychiatry 5. American Journal of Geriatric Psychiatry 6. Annals of Neurology 7. Archives of Neurology 8. Behavioral and Brain Sciences 9. Brain 10. Brain and Language 11. British Medical Journal 12. Clinical Neuropharmacology 13. Cognitive and Behavioral Neurology 14. Consciousness & Cognition 15. Cortex 16. Dementia and Geriatric Cognitive Disorders 17. Experimental Aging Research 18. Expert Opinion on Investigational Drugs 19. International Journal of Neuropsychopharmacology 20. International Journal of Psychiatry

34

21. International Psychogeriatrics 22. Journal of Alzheimer’s Disease 23. Journal of Neuroimaging 24. Journal of Neurology, Neurosurgery, and Psychiatry 25. Journal of the American Geriatrics Society 26. Journal of the American Medical Association (JAMA) 27. Journal of the International Neuropsychological Society 28. Neurobiology of Aging 29. Neurocase 30. Neurology 31. Neuropsychology 32. Neuropsychopharmacology 33. New England Journal of Medicine 34. Proceedings of the National Academy of Sciences 35. Psychiatry Research: Neuroimaging Section

MISCELLANEOUS: 1. Consultant, “Evaluating Prescrition Drugs Used To Treat Alzheimer’s Disease: Comparing

Effectiveness, Safety, and Price.” Consumer Reports Health, 2012. 2. Ad hoc grant reviewer, National Football League Charities Medical Research Grants, 2011. 3. Ad hoc grant reviewer, Brain and Cognition: Societal Innovation in Health Care, Education, and

Social Safety, Netherlands National Initiative for Brain and Cognition, 2011. 4. Ad hoc grant reviewer, Alzheimer Association, 1998-2001, 2005, 2007. 5. Ad hoc reviewer, National Center for Complementary and Alternative Medicine, Clinical Research

Review, June 12-13, 2006, July 2-3, 2007, February 19-20, 2008, June 22-3, 2009, October 30, 2009.

6. Ad hoc grant reviewer, Alzheimer’s Society (United Kingdom), 2005. 7. Ad hoc grant reviewer, John Douglas French Alzheimer’s Foundation, 1998-2002, 2005. 8. Ad hoc grant reviewer, Department of Veterans Affairs Career Development Award, 2002. 9. Reviewer, American Academy of Neurology Practice Parameters on Non-Cognitive Aspects of

Parkinson’s Disease, 2006. 10. Reviewer, American Psychiatric Association Guidelines for the diagnosis and management of

Alzheimer’s disease and other dementias, 2006. Reviewer, American Academy of Neurology Practice Parameter on Diagnosis of Dementia, 2001.

11. Peer reviewer, “Frontotemporal Degeneration, “British Medical Journal Best Practice Series. 12. Scientific session moderator, “Lewy Body Dementia Biomarker Symposium”, R13 funded

symposium, Atlanta, GA, April 25-27, 2010. 13. “Autism and Aging Workshop” participant, UNC-Chapel Hill (J. Piven, Organizer), March 19, 2010. 14. Collaborator, National Parkinson’s Foundation Center for Excellence in Parkinson’s Disease,

University of North Carolina at Chapel Hill, 2005-2008. 15. External Consultant, R01 MH043832, Maintenance Therapies in Late-Life Depression-III, C.F.

Reynolds, PI, 3/04 - 2/09. 16. Editorial Board, Treatment Goals for Patients with Alzheimer’s Disease. Oxford Institute for

Continuing Education, 2001-2002. 17. Consultant: Accera, Eisai, Forest, Glaxosmithkline, Johnson & Johnson, Medevation, Novartis,

Pfizer, Sanofi-Aventis, Warner-Lambert.

35

UNC – CHAPEL HILL: 2012- Director, Cognitive Neurology, UNC CSRA Brain & Body Health Clinic. 2012- Member, Scientific Review Subcommittee, Biomedical IRB, Office of Human Research

Ethics, UNC Chapel Hill. 2011- Mentor, Medical Student Training in Aging Research (MSTAR). 2010- Preceptor, Memory Disorders Clinic, Geriatric Medicine Fellowship, Center on Aging

and Health. 2010- Board Member, Center for the Study of Retired Athletes, UNC Chapel Hill.

Department of Neurology: 2012- Clinic Relocation Committee. 2010- Resident Applicant Interviewer. 2009- Compensation Committee. 2007- Faculty Organizer, Neurology Grand Rounds. 2006- Residency Evaluation Committee. 2005- Faculty Adviser, Student Interest Group in Neurology (SIGN). 2003- Division Head, Cognitive Neurology & Memory Disorders.